A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS.
Tumors or cancer of the URINARY BLADDER.
A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm but is often wrongly used as a synonym for "cancer." (From Dorland, 27th ed)
Cancer or tumors of the URETER which may cause obstruction leading to hydroureter, HYDRONEPHROSIS, and PYELONEPHRITIS. HEMATURIA is a common symptom.
Tumors or cancer of the URINARY TRACT in either the male or the female.
A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)
The flattened, funnel-shaped expansion connecting the URETER to the KIDNEY CALICES.
A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.
Cancer or tumors of the URETHRA. Benign epithelial tumors of the urethra usually consist of squamous and transitional cells. Primary urethral carcinomas are rare and typically of squamous cells. Urethral carcinoma is the only urological malignancy that is more common in females than in males.
The epithelial lining of the URINARY TRACT.
Used for excision of the urinary bladder.
A lesion with cytological characteristics associated with invasive carcinoma but the tumor cells are confined to the epithelium of origin, without invasion of the basement membrane.
A musculomembranous sac along the URINARY TRACT. URINE flows from the KIDNEYS into the bladder via the ureters (URETER), and is held there until URINATION.
A malignant neoplasm characterized by the formation of numerous, irregular, finger-like projections of fibrous stroma that is covered with a surface layer of neoplastic epithelial cells. (Stedman, 25th ed)
The instillation or other administration of drugs into the bladder, usually to treat local disease, including neoplasms.
Histochemical localization of immunoreactive substances using labeled antibodies as reagents.
Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.
Ability of neoplasms to infiltrate and actively destroy surrounding tissue.
Tumors or cancer of the UROGENITAL SYSTEM in either the male or the female.
A uroplakin subtype that heterodimerizes with UROPLAKIN IA to form a component of the asymmetric unit membrane found in urothelial cells.
Endoscopic examination, therapy or surgery of the urinary bladder.
One of a pair of thick-walled tubes that transports urine from the KIDNEY PELVIS to the URINARY BLADDER.
Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or body fluids. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids.
A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.
Tumors or cancer of the LIVER.
The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.
An invasive (infiltrating) CARCINOMA of the mammary ductal system (MAMMARY GLANDS) in the human BREAST.
Tumors or cancers of the KIDNEY.
A malignant skin neoplasm that seldom metastasizes but has potentialities for local invasion and destruction. Clinically it is divided into types: nodular, cicatricial, morphaic, and erythematoid (pagetoid). They develop on hair-bearing skin, most commonly on sun-exposed areas. Approximately 85% are found on the head and neck area and the remaining 15% on the trunk and limbs. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1471)
Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely.
A uroplakin subtype that heterodimerizes with UROPLAKIN IB to form a component of the asymmetric unit membrane found in urothelial cells.
A smooth, solid or cystic fibroepithelial (FIBROEPITHELIAL NEOPLASMS) tumor, usually found in the OVARIES but can also be found in the adnexal region and the KIDNEYS. It consists of a fibrous stroma with nests of epithelial cells that sometimes resemble the transitional cells lining the urinary bladder. Brenner tumors generally are benign and asymptomatic. Malignant Brenner tumors have been reported.
Two or more abnormal growths of tissue occurring simultaneously and presumed to be of separate origin. The neoplasms may be histologically the same or different, and may be found in the same or different sites.
Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue.
Tumors or cancer located in muscle tissue or specific muscles. They are differentiated from NEOPLASMS, MUSCLE TISSUE which are neoplasms composed of skeletal, cardiac, or smooth muscle tissue, such as MYOSARCOMA or LEIOMYOMA.
A malignant epithelial tumor with a glandular organization.
A tetraspanin domain-containing uroplakin subtype. It heterodimerizes with UROPLAKIN III to form a component of the asymmetric unit membrane found in urothelial cells.
A cell line derived from cultured tumor cells.
A tetraspanin domain-containing uroplakin subtype. It heterodimerizes with UROPLAKIN II to form a component of the asymmetric unit membrane found in urothelial cells.
Presence of blood in the urine.
Immunologic techniques based on the use of: (1) enzyme-antibody conjugates; (2) enzyme-antigen conjugates; (3) antienzyme antibody followed by its homologous enzyme; or (4) enzyme-antienzyme complexes. These are used histologically for visualizing or labeling tissue specimens.
The worsening of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis.
Death resulting from the presence of a disease in an individual, as shown by a single case report or a limited number of patients. This should be differentiated from DEATH, the physiological cessation of life and from MORTALITY, an epidemiological or statistical concept.
Malignant neoplasm arising from the epithelium of the BRONCHI. It represents a large group of epithelial lung malignancies which can be divided into two clinical groups: SMALL CELL LUNG CANCER and NON-SMALL-CELL LUNG CARCINOMA.
A substituted carcinogenic nitrosamine.
A noninvasive (noninfiltrating) carcinoma of the breast characterized by a proliferation of malignant epithelial cells confined to the mammary ducts or lobules, without light-microscopy evidence of invasion through the basement membrane into the surrounding stroma.
DNA present in neoplastic tissue.
A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.
Carcinoma characterized by bands or cylinders of hyalinized or mucinous stroma separating or surrounded by nests or cords of small epithelial cells. When the cylinders occur within masses of epithelial cells, they give the tissue a perforated, sievelike, or cribriform appearance. Such tumors occur in the mammary glands, the mucous glands of the upper and lower respiratory tract, and the salivary glands. They are malignant but slow-growing, and tend to spread locally via the nerves. (Dorland, 27th ed)
Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses.
A class of fibrous proteins or scleroproteins that represents the principal constituent of EPIDERMIS; HAIR; NAILS; horny tissues, and the organic matrix of tooth ENAMEL. Two major conformational groups have been characterized, alpha-keratin, whose peptide backbone forms a coiled-coil alpha helical structure consisting of TYPE I KERATIN and a TYPE II KERATIN, and beta-keratin, whose backbone forms a zigzag or pleated sheet structure. alpha-Keratins have been classified into at least 20 subtypes. In addition multiple isoforms of subtypes have been found which may be due to GENE DUPLICATION.
A cystic dilation of the EPIDIDYMIS, usually in the head portion (caput epididymis). The cyst fluid contains dead SPERMATOZOA and can be easily differentiated from TESTICULAR HYDROCELE and other testicular lesions.
Excision of kidney.
Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm.
RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.
An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7)
Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system.
A carcinoma composed mainly of epithelial elements with little or no stroma. Medullary carcinomas of the breast constitute 5%-7% of all mammary carcinomas; medullary carcinomas of the thyroid comprise 3%-10% of all thyroid malignancies. (From Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1141; Segen, Dictionary of Modern Medicine, 1992)
Experimental transplantation of neoplasms in laboratory animals for research purposes.
A circumscribed benign epithelial tumor projecting from the surrounding surface; more precisely, a benign epithelial neoplasm consisting of villous or arborescent outgrowths of fibrovascular stroma covered by neoplastic cells. (Stedman, 25th ed)
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
Nuclear phosphoprotein encoded by the p53 gene (GENES, P53) whose normal function is to control CELL PROLIFERATION and APOPTOSIS. A mutant or absent p53 protein has been found in LEUKEMIA; OSTEOSARCOMA; LUNG CANCER; and COLORECTAL CANCER.
A infiltrating (invasive) breast cancer, relatively uncommon, accounting for only 5%-10% of breast tumors in most series. It is often an area of ill-defined thickening in the breast, in contrast to the dominant lump characteristic of ductal carcinoma. It is typically composed of small cells in a linear arrangement with a tendency to grow around ducts and lobules. There is likelihood of axillary nodal involvement with metastasis to meningeal and serosal surfaces. (DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1205)
An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
Tumors or cancer of the LUNG.
The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.
The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.
A group of carcinomas which share a characteristic morphology, often being composed of clusters and trabecular sheets of round "blue cells", granular chromatin, and an attenuated rim of poorly demarcated cytoplasm. Neuroendocrine tumors include carcinoids, small ("oat") cell carcinomas, medullary carcinoma of the thyroid, Merkel cell tumor, cutaneous neuroendocrine carcinoma, pancreatic islet cell tumors, and pheochromocytoma. Neurosecretory granules are found within the tumor cells. (Segen, Dictionary of Modern Medicine, 1992)
Tumors or cancer of the NASOPHARYNX.
A mucosal tumor of the urinary bladder or nasal cavity in which proliferating epithelium is invaginated beneath the surface and is more smoothly rounded than in other papillomas. (Stedman, 25th ed)
Substances that inhibit or prevent the proliferation of NEOPLASMS.
Tumors or cancer of the THYROID GLAND.
Tumors or cancer of the human BREAST.
The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION.
A type II keratin found associated with KERATIN-19 in ductal epithelia and gastrointestinal epithelia.
A specific pair of GROUP C CHROMSOMES of the human chromosome classification.
A CELL CYCLE and tumor growth marker which can be readily detected using IMMUNOCYTOCHEMISTRY methods. Ki-67 is a nuclear antigen present only in the nuclei of cycling cells.
Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.
A tumor of both low- and high-grade malignancy. The low-grade grow slowly, appear in any age group, and are readily cured by excision. The high-grade behave aggressively, widely infiltrate the salivary gland and produce lymph node and distant metastases. Mucoepidermoid carcinomas account for about 21% of the malignant tumors of the parotid gland and 10% of the sublingual gland. They are the most common malignant tumor of the parotid. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p575; Holland et al., Cancer Medicine, 3d ed, p1240)
A mixed adenocarcinoma and squamous cell or epidermoid carcinoma.
Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.
An increase in the number of cells in a tissue or organ without tumor formation. It differs from HYPERTROPHY, which is an increase in bulk without an increase in the number of cells.
Tumors or cancer of the pelvic region.
The three membranous semicircular ducts within the bony semicircular canals. They open into the UTRICLE through five openings. Each duct has at one end a sensory area called the ampullary crest. AMPULLARY HAIR CELLS of the crests sense the movement of ENDOLYMPH resulting from rotation of the head.
A potent nitrofuran derivative tumor initiator. It causes bladder tumors in all animals studied and is mutagenic to many bacteria.
A type I keratin expressed predominately in gastrointestinal epithelia, MERKEL CELLS, and the TASTE BUDS of the oral mucosa.
Diseases of the domestic dog (Canis familiaris). This term does not include diseases of wild dogs, WOLVES; FOXES; and other Canidae for which the heading CARNIVORA is used.
An adenocarcinoma characterized by the presence of cells resembling the glandular cells of the ENDOMETRIUM. It is a common histological type of ovarian CARCINOMA and ENDOMETRIAL CARCINOMA. There is a high frequency of co-occurrence of this form of adenocarcinoma in both tissues.
A variation of the PCR technique in which cDNA is made from RNA via reverse transcription. The resultant cDNA is then amplified using standard PCR protocols.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
Pathological processes that tend eventually to become malignant. (From Dorland, 27th ed)
Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)
Tumor suppressor genes located on the short arm of human chromosome 17 and coding for the phosphoprotein p53.
The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.
RNA present in neoplastic tissue.
A highly malignant, primitive form of carcinoma, probably of germinal cell or teratomatous derivation, usually arising in a gonad and rarely in other sites. It is rare in the female ovary, but in the male it accounts for 20% of all testicular tumors. (From Dorland, 27th ed & Holland et al., Cancer Medicine, 3d ed, p1595)
Elements of limited time intervals, contributing to particular results or situations.
Tumors or cancer of the ESOPHAGUS.
Antibodies produced by a single clone of cells.
Tumors or cancer of the MOUTH.
A carcinoma arising from MERKEL CELLS located in the basal layer of the epidermis and occurring most commonly as a primary neuroendocrine carcinoma of the skin. Merkel cells are tactile cells of neuroectodermal origin and histologically show neurosecretory granules. The skin of the head and neck are a common site of Merkel cell carcinoma, occurring generally in elderly patients. (Holland et al., Cancer Medicine, 3d ed, p1245)
Malignant neoplasms involving the ductal systems of any of a number of organs, such as the MAMMARY GLANDS, the PANCREAS, the PROSTATE, or the LACRIMAL GLAND.
A condition in which there is a change of one adult cell type to another similar adult cell type.
The loss of one allele at a specific locus, caused by a deletion mutation; or loss of a chromosome from a chromosome pair, resulting in abnormal HEMIZYGOSITY. It is detected when heterozygous markers for a locus appear monomorphic because one of the ALLELES was deleted.
The degree of replication of the chromosome set in the karyotype.
Material, usually gauze or absorbent cotton, used to cover and protect wounds, to seal them from contact with air or bacteria. (From Dorland, 27th ed)
Inflammation of the URINARY BLADDER, either from bacterial or non-bacterial causes. Cystitis is usually associated with painful urination (dysuria), increased frequency, urgency, and suprapubic pain.
Removal and pathologic examination of specimens in the form of small pieces of tissue from the living body.
Methods which attempt to express in replicable terms the level of CELL DIFFERENTIATION in neoplasms as increasing ANAPLASIA correlates with the aggressiveness of the neoplasm.
One or more layers of EPITHELIAL CELLS, supported by the basal lamina, which covers the inner or outer surfaces of the body.
Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.)
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
A malignant neoplasm of the ADRENAL CORTEX. Adrenocortical carcinomas are unencapsulated anaplastic (ANAPLASIA) masses sometimes exceeding 20 cm or 200 g. They are more likely to be functional than nonfunctional, and produce ADRENAL CORTEX HORMONES that may result in hypercortisolism (CUSHING SYNDROME); HYPERALDOSTERONISM; and/or VIRILISM.
Temporary or permanent diversion of the flow of urine through the ureter away from the URINARY BLADDER in the presence of a bladder disease or after cystectomy. There is a variety of techniques: direct anastomosis of ureter and bowel, cutaneous ureterostomy, ileal, jejunal or colon conduit, ureterosigmoidostomy, etc. (From Campbell's Urology, 6th ed, p2654)
One of the mechanisms by which CELL DEATH occurs (compare with NECROSIS and AUTOPHAGOCYTOSIS). Apoptosis is the mechanism responsible for the physiological deletion of cells and appears to be intrinsically programmed. It is characterized by distinctive morphologic changes in the nucleus and cytoplasm, chromatin cleavage at regularly spaced sites, and the endonucleolytic cleavage of genomic DNA; (DNA FRAGMENTATION); at internucleosomal sites. This mode of cell death serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth.
Surgery performed on the urinary tract or its parts in the male or female. For surgery of the male genitalia, UROLOGIC SURGICAL PROCEDURES, MALE is available.
Tumors or cancer of the COLON.
Transplantation between animals of different species.
A variant of well-differentiated epidermoid carcinoma that is most common in the oral cavity, but also occurs in the larynx, nasal cavity, esophagus, penis, anorectal region, vulva, vagina, uterine cervix, and skin, especially on the sole of the foot. Most intraoral cases occur in elderly male abusers of smokeless tobacco. The treatment is surgical resection. Radiotherapy is not indicated, as up to 30% treated with radiation become highly aggressive within six months. (Segen, Dictionary of Modern Medicine, 1992)
Recesses of the kidney pelvis which divides into two wide, cup-shaped major renal calices, with each major calix subdivided into 7 to 14 minor calices. Urine empties into a minor calix from collecting tubules, then passes through the major calix, renal pelvis, and ureter to enter the urinary bladder. (From Moore, Clinically Oriented Anatomy, 3d ed, p211)
An expression of the number of mitoses found in a stated number of cells.
A poorly differentiated adenocarcinoma in which the nucleus is pressed to one side by a cytoplasmic droplet of mucus. It usually arises in the gastrointestinal system.
All of the processes involved in increasing CELL NUMBER including CELL DIVISION.
Experimentally induced new abnormal growth of TISSUES in animals to provide models for studying human neoplasms.
Diagnosis of the type and, when feasible, the cause of a pathologic process by means of microscopic study of cells in an exudate or other form of body fluid. (Stedman, 26th ed)
The duct which coveys URINE from the pelvis of the KIDNEY through the URETERS, BLADDER, and URETHRA.
Tumors or cancer of the STOMACH.
Tumors or cancer of the SKIN.
Genes that inhibit expression of the tumorigenic phenotype. They are normally involved in holding cellular growth in check. When tumor suppressor genes are inactivated or lost, a barrier to normal proliferation is removed and unregulated growth is possible.
The infiltrating of tissue specimens with paraffin, as a supporting substance, to prepare for sectioning with a microtome.
Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.
Cancers or tumors of the PENIS or of its component tissues.
Variation in a population's DNA sequence that is detected by determining alterations in the conformation of denatured DNA fragments. Denatured DNA fragments are allowed to renature under conditions that prevent the formation of double-stranded DNA and allow secondary structure to form in single stranded fragments. These fragments are then run through polyacrylamide gels to detect variations in the secondary structure that is manifested as an alteration in migration through the gels.
A pathologic process consisting of the proliferation of blood vessels in abnormal tissues or in abnormal positions.
A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS BREVIFOLIA. It stabilizes MICROTUBULES in their polymerized form leading to cell death.
Identification of proteins or peptides that have been electrophoretically separated by blot transferring from the electrophoresis gel to strips of nitrocellulose paper, followed by labeling with antibody probes.
A tumor of undifferentiated (anaplastic) cells of large size. It is usually bronchogenic. (From Dorland, 27th ed)
Tomography using x-ray transmission and a computer algorithm to reconstruct the image.
Nuclear antigen with a role in DNA synthesis, DNA repair, and cell cycle progression. PCNA is required for the coordinated synthesis of both leading and lagging strands at the replication fork during DNA replication. PCNA expression correlates with the proliferation activity of several malignant and non-malignant cell types.
Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations.
A family of small, non-enveloped DNA viruses infecting birds and most mammals, especially humans. They are grouped into multiple genera, but the viruses are highly host-species specific and tissue-restricted. They are commonly divided into hundreds of papillomavirus "types", each with specific gene function and gene control regions, despite sequence homology. Human papillomaviruses are found in the genera ALPHAPAPILLOMAVIRUS; BETAPAPILLOMAVIRUS; GAMMAPAPILLOMAVIRUS; and MUPAPILLOMAVIRUS.
Proteins that are normally involved in holding cellular growth in check. Deficiencies or abnormalities in these proteins may lead to unregulated cell growth and tumor development.
Abnormal number or structure of chromosomes. Chromosome aberrations may result in CHROMOSOME DISORDERS.
The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence.
Tumors or cancer of the UTERINE CERVIX.
Infection with flukes (trematodes) of the genus SCHISTOSOMA. Three species produce the most frequent clinical diseases: SCHISTOSOMA HAEMATOBIUM (endemic in Africa and the Middle East), SCHISTOSOMA MANSONI (in Egypt, northern and southern Africa, some West Indies islands, northern 2/3 of South America), and SCHISTOSOMA JAPONICUM (in Japan, China, the Philippines, Celebes, Thailand, Laos). S. mansoni is often seen in Puerto Ricans living in the United States.
Antimetabolites that are useful in cancer chemotherapy.
A type of IN SITU HYBRIDIZATION in which target sequences are stained with fluorescent dye so their location and size can be determined using fluorescence microscopy. This staining is sufficiently distinct that the hybridization signal can be seen both in metaphase spreads and in interphase nuclei.
A variety of simple repeat sequences that are distributed throughout the GENOME. They are characterized by a short repeat unit of 2-8 basepairs that is repeated up to 100 times. They are also known as short tandem repeats (STRs).
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)
An adenocarcinoma of the thyroid gland, in which the cells are arranged in the form of follicles. (From Dorland, 27th ed)
Mapping of the KARYOTYPE of a cell.
A cell surface protein-tyrosine kinase receptor that is overexpressed in a variety of ADENOCARCINOMAS. It has extensive homology to and heterodimerizes with the EGF RECEPTOR, the ERBB-3 RECEPTOR, and the ERBB-4 RECEPTOR. Activation of the erbB-2 receptor occurs through heterodimer formation with a ligand-bound erbB receptor family member.
An active immunizing agent and a viable avirulent attenuated strain of Mycobacterium tuberculosis, var. bovis, which confers immunity to mycobacterial infections. It is used also in immunotherapy of neoplasms due to its stimulation of antibodies and non-specific immunity.
Surgical excision of one or more lymph nodes. Its most common use is in cancer surgery. (From Dorland, 28th ed, p966)
Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.
An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.
A nonparametric method of compiling LIFE TABLES or survival tables. It combines calculated probabilities of survival and estimates to allow for observations occurring beyond a measurement threshold, which are assumed to occur randomly. Time intervals are defined as ending each time an event occurs and are therefore unequal. (From Last, A Dictionary of Epidemiology, 1995)
An adenocarcinoma producing mucin in significant amounts. (From Dorland, 27th ed)
The phenotypic manifestation of a gene or genes by the processes of GENETIC TRANSCRIPTION and GENETIC TRANSLATION.
Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included.
The malignant stem cells of TERATOCARCINOMAS, which resemble pluripotent stem cells of the BLASTOCYST INNER CELL MASS. The EC cells can be grown in vitro, and experimentally induced to differentiate. They are used as a model system for studying early embryonic cell differentiation.
A technique that localizes specific nucleic acid sequences within intact chromosomes, eukaryotic cells, or bacterial cells through the use of specific nucleic acid-labeled probes.
Progressive restriction of the developmental potential and increasing specialization of function that leads to the formation of specialized cells, tissues, and organs.
An inducibly-expressed subtype of prostaglandin-endoperoxide synthase. It plays an important role in many cellular processes and INFLAMMATION. It is the target of COX2 INHIBITORS.
An EPITHELIUM with MUCUS-secreting cells, such as GOBLET CELLS. It forms the lining of many body cavities, such as the DIGESTIVE TRACT, the RESPIRATORY TRACT, and the reproductive tract. Mucosa, rich in blood and lymph vessels, comprises an inner epithelium, a middle layer (lamina propria) of loose CONNECTIVE TISSUE, and an outer layer (muscularis mucosae) of SMOOTH MUSCLE CELLS that separates the mucosa from submucosa.
A thyroid neoplasm of mixed papillary and follicular arrangement. Its biological behavior and prognosis is the same as that of a papillary adenocarcinoma of the thyroid. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1271)
A set of techniques used when variation in several variables has to be studied simultaneously. In statistics, multivariate analysis is interpreted as any analytic method that allows simultaneous study of two or more dependent variables.
An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.
A cell surface receptor involved in regulation of cell growth and differentiation. It is specific for EPIDERMAL GROWTH FACTOR and EGF-related peptides including TRANSFORMING GROWTH FACTOR ALPHA; AMPHIREGULIN; and HEPARIN-BINDING EGF-LIKE GROWTH FACTOR. The binding of ligand to the receptor causes activation of its intrinsic tyrosine kinase activity and rapid internalization of the receptor-ligand complex into the cell.
Tumors or cancer of the gallbladder.
Liquid by-product of excretion produced in the kidneys, temporarily stored in the bladder until discharge through the URETHRA.
A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.
The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065)
Tumors or cancer of ENDOMETRIUM, the mucous lining of the UTERUS. These neoplasms can be benign or malignant. Their classification and grading are based on the various cell types and the percent of undifferentiated cells.
In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test.
An adenocarcinoma characterized by the presence of varying combinations of clear and hobnail-shaped tumor cells. There are three predominant patterns described as tubulocystic, solid, and papillary. These tumors, usually located in the female reproductive organs, have been seen more frequently in young women since 1970 as a result of the association with intrauterine exposure to diethylstilbestrol. (From Holland et al., Cancer Medicine, 3d ed)
Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.
A negative regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins.
The relationship between the dose of an administered drug and the response of the organism to the drug.
Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake.
Established cell cultures that have the potential to propagate indefinitely.
Drug therapy given to augment or stimulate some other form of treatment such as surgery or radiation therapy. Adjuvant chemotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment.
Neoplasms of the skin and mucous membranes caused by papillomaviruses. They are usually benign but some have a high risk for malignant progression.
The first alpha-globulins to appear in mammalian sera during FETAL DEVELOPMENT and the dominant serum proteins in early embryonic life.
Tumors or cancer of the TONGUE.
The uptake of naked or purified DNA by CELLS, usually meaning the process as it occurs in eukaryotic cells. It is analogous to bacterial transformation (TRANSFORMATION, BACTERIAL) and both are routinely employed in GENE TRANSFER TECHNIQUES.
Detection of RNA that has been electrophoretically separated and immobilized by blotting on nitrocellulose or other type of paper or nylon membrane followed by hybridization with labeled NUCLEIC ACID PROBES.
Biochemical identification of mutational changes in a nucleotide sequence.
The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment.
The original member of the family of endothelial cell growth factors referred to as VASCULAR ENDOTHELIAL GROWTH FACTORS. Vascular endothelial growth factor-A was originally isolated from tumor cells and referred to as "tumor angiogenesis factor" and "vascular permeability factor". Although expressed at high levels in certain tumor-derived cells it is produced by a wide variety of cell types. In addition to stimulating vascular growth and vascular permeability it may play a role in stimulating VASODILATION via NITRIC OXIDE-dependent pathways. Alternative splicing of the mRNA for vascular endothelial growth factor A results in several isoforms of the protein being produced.
Studies which start with the identification of persons with a disease of interest and a control (comparison, referent) group without the disease. The relationship of an attribute to the disease is examined by comparing diseased and non-diseased persons with regard to the frequency or levels of the attribute in each group.
Clinical conditions caused by an abnormal chromosome constitution in which there is extra or missing chromosome material (either a whole chromosome or a chromosome segment). (from Thompson et al., Genetics in Medicine, 5th ed, p429)
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
A malignant cystic or semicystic neoplasm. It often occurs in the ovary and usually bilaterally. The external surface is usually covered with papillary excrescences. Microscopically, the papillary patterns are predominantly epithelial overgrowths with differentiated and undifferentiated papillary serous cystadenocarcinoma cells. Psammoma bodies may be present. The tumor generally adheres to surrounding structures and produces ascites. (From Hughes, Obstetric-Gynecologic Terminology, 1972, p185)
An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA.

Long-term transplantability and morphological stability of three experimentally induced urinary bladder carcinomas in rats. (1/1469)

Three transitional cell carcinomas induced in Fischer 344 rats by a methylcholanthrene pellet or a foreign body inserted locally into the bladder have been serially transplanted in the syngeneic strain for up to 6.5 years. There have been no changes in the individual morphological characteristics of the tumors during this time. Cells cultured in vitro for varying numbers of passages reproduce regularly the morphology of each tumor when they are injected back into the animals and results from a microcytotoxicity assay for cellular immunity indicate that they retain a common, bladder tumor-specific antigen. These tumors are useful for research in turmo biology and are offered to other scientists seeking transplantable carcinomas for experimentation.  (+info)

Natural history of papillary lesions of the urinary bladder in schistosomiasis. (2/1469)

Variable epithelial hyperplasia was observed in urinary bladder of nine capuchin monkeys (Cebus apella) when examined at cystotomy 94 to 164 weeks after infection with Schistosoma haematobium. These hosts were followed for 24 to 136 weeks postcystotomy to determine the status of bladder lesions in relation to duration of infection and to ascertain whether lesion samples removed at cystotomy reestablished themselves in autologous and heterologous transfers. There was involution of urothelial hyperplasia in eight of nine animals and no evidence for establishment of transplanted bladder lesions.  (+info)

Differential regulation of p21waf-1/cip-1 and Mdm2 by etoposide: etoposide inhibits the p53-Mdm2 autoregulatory feedback loop. (3/1469)

The Mdm2 protein is frequently overexpressed in human non-seminomatous germ cell tumours and transitional carcinoma of the bladder where it may contribute to tolerance of wtp53. Mdm2 forms an autoregulatory feedback loop with p53; the Mdm2 gene is responsive to transactivation by p53 and once synthesized the Mdm2 protein terminates the p53 response. We show here that the topoisomerase poison etoposide, like ultra violet irradiation, inhibits Mdm2 synthesis. Cytotoxic concentrations of etoposide (IC90 for > 3 h) result in inhibition of Mdm2 induction at both the RNA and protein level. Rapid apoptosis ensues. Global transcription is not inhibited: p21waf-1/cip1 and GADD45 expression increase in a dose dependent manner. Inhibition of Mdm2 synthesis depends on the continuous presence of etoposide, suggesting the DNA damage may prevent transcription. Downregulation of Mdm2 transcript occurs in cells expressing HPV16-E6 suggesting that inhibition of Mdm2 transcription is p53-independent. When cells are -treated with a pulse (1 h) of etoposide and reincubated in drug free medium, Mdm2 synthesis commences immediately after damage is repaired (3 h) and the p53 response is attenuated. Induction of apoptosis and loss of clonogenicity are 3-5-fold lower under pulse treatment conditions. This is the first observation of inhibition of Mdm2 transcription following treatment with topoisomerase (topo II) poisons, a feature that may be useful in tumour types where p53 is tolerated by overexpression of Mdm2.  (+info)

Tumor-induced interleukin-10 inhibits type 1 immune responses directed at a tumor antigen as well as a non-tumor antigen present at the tumor site. (4/1469)

Interleukin (IL)-10 is a potent immunosuppressive cytokine that has been found to be present at the tumor site in a wide variety of human cancers, including transitional cell carcinoma of the bladder. Using a murine bladder tumor (MB49), which we show to express the male transplantation antigen (HY), we tested the hypothesis that IL-10 at the tumor site can block the generation of a tumor-specific type 1 immune response. We show that, despite its expression of HY, MB49 fails to prime for an HY-specific type 1 (IFN-gamma) response in normal female mice. Although MB49 does not constitutively produce IL-10, our data support a model whereby MB49 induces infiltrating cells to produce IL-10. This feature rendered the IL-10 knockout (KO) mouse, whose infiltrating cells are incapable of IL-10 production, a suitable model in which to study MB49 in the absence of IL-10. When injected into IL-10 KO mice, MB49 does prime for an HY-specific, type 1 immune response. Furthermore, IL-10 KO mice show prolonged survival and an increased capacity to reject tumors as compared with normal mice. We also tested the ability of tumor-induced IL-10 to inhibit immunization to a non-tumor antigen present at the tumor site. When vaccinia virus encoding beta-galactosidase (beta-gal) is injected into the tumors of normal mice, no beta-gal-specific IFN-gamma response is mounted. However, when this same viral construct is injected into the tumors of IL-10 KO mice, it produces a strong beta-gal-specific, IFN-gamma response. These studies demonstrate that tumor-induced IL-10 can block the generation of a tumor-specific type 1 immune response as well as subvert attempts to elicit a type 1 immune response to a non-tumor antigen at the tumor site.  (+info)

Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. (5/1469)

Epidermal growth factor receptor (EGFR) regulates the growth and progression of human transitional cell carcinoma (TCC) of the bladder. We have shown that therapy targeting EGFR inhibited the growth of human TCC established orthotopically in nude mice. The purpose of this study was to evaluate whether EGFR-directed therapy affects angiogenesis associated with the growth and metastasis of human TCC. We determined the cytostatic effect and the effect on production of angiogenic factors after in vitro treatment of the human TCC cell line 253J B-V with MAb C225, a chimerized monoclonal anti-EGFR antibody. The 253J B-V cells were implanted orthotopically into athymic nude mice, and established tumors (4 weeks) were treated with i.p. MAb C225. Expression of the angiogenic factors vascular endothelial growth factor (VEGF), interleukin-8 (IL-8), and basic fibroblast growth factor (bFGF) was evaluated by immunohistochemistry and in situ mRNA hybridization analyses and correlated with microvessel density evaluated after immunohistochemical staining with anti-CD31. In vitro treatment with MAb C225 inhibited mRNA and protein production of VEGF, IL-8, and bFGF by 253J B-V cells in a dose-dependent manner. MAb C225 therapy of nude mice with established TCCs growing orthotopically resulted in inhibition of growth and metastasis compared with controls (P <0.0005). VEGF, IL-8, and bFGF expression was significantly lower in treated tumors than in controls. The down-regulation of these angiogenic factors preceded the involution of blood vessels. These studies indicate that therapy with anti-EGFR MAb C225 has a significant antitumor effect mediated, in part, by inhibition of angiogenesis.  (+info)

Interleukin-2 gene transfer into human transitional cell carcinoma of the urinary bladder. (6/1469)

Transitional cell carcinoma of the bladder is one of the human cancers most responsive to immunotherapy, and local interleukin-2 (IL-2) production appears to be an important requirement for immunotherapy to be effective. In this study, we engineered two human bladder cancer cell lines (RT112 and EJ) to constitutively release human IL-2 by retroviral vector-mediated gene transfer. Following infection and selection, stable and consistent production of biologically active IL-2 was demonstrated at both the mRNA and the protein level. Morphology, in vitro growth rate and proliferation, as well as other cytokine gene mRNA or membrane adhesion receptor expression, were not altered in IL-2 transduced cells as compared to their parental or control vector-infected counterparts. Moreover, IL-2 engineered cells lost their tumorigenicity into nu/nu mice and the mechanism of rejection appeared to involve multiple host effector cell populations, among which a prominent role was played by neutrophils and radiosensitive cells. These findings may offer support to the development of an IL-2-based gene therapy approach to human bladder cancer.  (+info)

Urinary bladder transitional cell carcinogenesis is associated with down-regulation of NF1 tumor suppressor gene in vivo and in vitro. (7/1469)

The NF1 gene product (neurofibromin) is known to act as a tumor suppressor protein by inactivating ras. The best documented factors involved in urinary bladder transitional cell carcinoma (TCC) are ras proto-oncogene activation and p53 suppressor gene mutations. This is the first study reporting alterations in NF1 gene expression in TCC. We examined NF1 gene expression in a total of 29 surgical urinary bladder TCC specimens representing grades 1 to 3 and in three cell lines, RT4, 5637, and T24 (representing grades 1 to 3, respectively). Decreased NF1 gene expression was observed in 23 of 29 (83%) TCC specimens as estimated by immunohistochemistry, the decrease being more pronounced in high-grade tumors. NF1 mRNA levels were markedly lower in TCC tissue compared with adjacent non-neoplastic urothelium, as studied by in situ hybridization for grade 3 TCC. Immunohistochemistry and Western blotting demonstrated that TCC cell lines expressed NF1 protein at different levels, expression being almost undetectable in T24 (grade 3) cells. Northern blotting for cell lines demonstrated reduced NF1 mRNA levels in grade 3 TCC cells. Reverse transcription polymerase chain reaction for cell lines and selected grade 2 and grade 3 tissue samples demonstrated NF1 type II mRNA isoform predominance in all samples studied. Our results show that both NF1 mRNA and protein levels are decreased in high-grade TCC, suggesting that alterations of NF1 gene expression may be involved in bladder TCC carcinogenesis.  (+info)

Overexpression of the wild type p73 gene in human bladder cancer. (8/1469)

p73, a first p53 relative, was recently identified and shown to be monoallelically expressed in a number of different human tissues. To determine the potential role of this gene in human bladder cancer, we investigated p73 expression levels, allelic expression patterns, and analysed p73 mutations in 23 unselected primary invasive bladder cancers with matched normal tissues and in seven bladder cancer cell lines. In a comparison between normal and tumor tissues using quantitative RT-PCR analysis, we found that p73 was overexpressed in 22/23 bladder cancers, sometimes as great as 20-fold. Allelic expression analysis using a C/T polymorphism in exon 2 and a newly identified T/C polymorphism in exon 5 revealed that p73 was biallelically expressed in both normal bladder and cancer tissues, suggesting that p73 is not imprinted in bladder tissue. Mutation screening of the p73 gene in bladder cancer DNAs using denaturing high-performance liquid chromatography analysis and DNA sequencing revealed no tumor-specific mutations in any coding exons of the p73 gene. These data suggest that the p73 is unlikely to be a tumor suppressor gene, but that overexpression of p73 may contribute to tumorigenesis in bladder cancer.  (+info)

Treatment options vary with the location of the tumor, but in general, require surgical excision. Installation of bacille Calmette-Guerin (BCG) or mitomycin C may be used in selected cases as an alternative to surgery in some cases .. A critical part of the management of patients with transitional cell carcinomas is an awareness of the high rate of recurrence due to a field effect on the urothelium. Approximately 40% of patients with an upper urinary tract transitional cell carcinoma will go on to develop one or more TCCs of the bladder, and approximately 2-4% of patients with a bladder transitional cell carcinoma will go on to develop one or more TCCs of the renal pelvis or ureter .. ...
TY - JOUR. T1 - Granulocyte-colony stimulating factor receptor expression on human transitional cell carcinoma of the bladder. AU - Tachibana, Masaaki. AU - Miyakawa, Ayako. AU - Uchida, Atsushi. AU - Sumitomo, Makoto. AU - Nakamura, Kayoko. AU - Murai, Masaru. PY - 1997/12/1. Y1 - 1997/12/1. N2 - Receptors for granulocyte-colony stimulating factor (G-CSFR) have been confirmed on the cell surfaces of several nonhaematopoietic cell types, including bladder cancer cells. This observation has naturally led to the hypothesis that the expression of G-CSFR on these cells may enhance their growth by G-CSF. In this study, the expression of G-CSFR was determined both in established human bladder cancer cell lines and primary bladder cancers. We studied five different human bladder cancer cell lines (KU-1, KU-7, T-24, NBT-2 and KK) and 26 newly diagnosed bladder tumors. G-CSFR mRNA expressions on cultured cell lines were determined using the reverse transcriptase-polymerase chain reaction (RT-PCR) method. ...
Phase I study of a 3-drug regimen of gemcitabine/cisplatin/pemetrexed in patients with metastatic transitional cell carcinoma of the urothelium.
A look at the following clinical trial: Broccoli Sprout Extract in Treating Patients With Transitional Cell Bladder Cancer Undergoing Surgery.
Fresh, superficial transitional cell carcinomas (TCCs) of low-grade atypia (3 grade I, Ta; 6 grade II, Ta), as well as primary cultures derived from them were labeled with [35S]methionine for 16 h, between 2 and 6 days after inoculation. Whole protein extracts were subjected to IEF (isoelectric focu …
Congratulations! You have found the Transitional cell carcinoma Forum on Forum Jar. This forum is a place where people who are interested in Transitional cell carcinoma come together and discuss about Transitional cell carcinoma. Please use the message board below to post anything related to Transitional cell carcinoma . If you are interested in other similar forums, please check out the Related Forums section on the right. If you like this forum, please dont forget to tell your friends about Forum Jar ...
TY - JOUR. T1 - Transitional cell carcinoma of the renal pelvis with chriocarcinomatous differentiation. Immunohistochemical and immunoelectron microscopic assessment of human chorionic gonadotropin production by transitional cell carcinoma of the urinary bladder. AU - Grammatico, Dino. AU - Grignon, David J.. AU - Eberwein, Parker. AU - Shepherd, R. Roderick. AU - Hearn, Stephen A.. AU - Walton, John C.. PY - 1993/3/1. Y1 - 1993/3/1. N2 - Background. There have been 12 documented cases of choriocarcinoma arising in the urinary bladder, either alone or in combination with other epithelial tumors. It has been shown that some high‐grade transitional cell carcinomas (TCC), without obvious syncytiotrophoblastic elements, can produce human chorionic gonadotropins (HCG). Methods. A case of choriocarcinoma, in association with high‐grade TCC of the renal pelvis, was encountered in an 80‐year‐old man. For additional evaluation of HCG production by TCC, 25 consecutive cases of invasive ...
Welcome to the Pathology Education Informational Resource (PEIR) Digital Library, a multidisciplinary public access image database for use in medical education. ...
Welcome to the Pathology Education Informational Resource (PEIR) Digital Library, a multidisciplinary public access image database for use in medical education. ...
We use cookies to ensure that we give you the best experience on our website. If you click Continue well assume that you are happy to receive all cookies and you wont see this message again. Click Find out more for information on how to change your cookie settings ...
We use cookies to ensure that we give you the best experience on our website. If you click Continue well assume that you are happy to receive all cookies and you wont see this message again. Click Find out more for information on how to change your cookie settings ...
Noninvasive transitional cell carcinomas of the bladder can have two distinct morphologies suggesting they contain different genetic alterations. Papillary transitional cell carcinomas (Ta tumors) are often multifocal and only occasionally progress, whereas flat tumors (carcinomas in situ, CIS), frequently progress to invasive disease. We examined 216 bladder tumors of various stages and histopathologies for two genetic alterations previously described to be of importance in bladder tumorigenesis. Loss of heterozygosity of chromosome 9 was observed in 24 of 70 (34%) Ta tumors but was present in only 3 of 24 (12%) CIS and dysplasia lesions (P = 0.04). In contrast, only 1 of 36 (3%) Ta tumors contained a p53 gene mutation compared to 15 of 23 (65%) CIS and dysplasias (P , 0.001), a frequency comparable to that observed in muscle invasive tumors (25 of 49; 51%). The presence of p53 mutations in CIS and dysplasia could explain their propensities to progress since these mutations are known to ...
Noninvasive transitional cell carcinomas of the bladder can have two distinct morphologies suggesting they contain different genetic alterations. Papillary transitional cell carcinomas (Ta tumors) are often multifocal and only occasionally progress, whereas flat tumors (carcinomas in situ, CIS), frequently progress to invasive disease. We examined 216 bladder tumors of various stages and histopathologies for two genetic alterations previously described to be of importance in bladder tumorigenesis. Loss of heterozygosity of chromosome 9 was observed in 24 of 70 (34%) Ta tumors but was present in only 3 of 24 (12%) CIS and dysplasia lesions (P = 0.04). In contrast, only 1 of 36 (3%) Ta tumors contained a p53 gene mutation compared to 15 of 23 (65%) CIS and dysplasias (P , 0.001), a frequency comparable to that observed in muscle invasive tumors (25 of 49; 51%). The presence of p53 mutations in CIS and dysplasia could explain their propensities to progress since these mutations are known to ...
TY - JOUR. T1 - Elective endoscopic management of transitional cell carcinoma first diagnosed in the upper urinary tract. AU - Thompson, R. Houston. AU - Krambeck, Amy. AU - Lohse, Christine M.. AU - Elliott, Daniel S.. AU - Patterson, David E.. AU - Blute, Michael L.. PY - 2008/11. Y1 - 2008/11. N2 - OBJECTIVE: To report our experience using ureteroscopic or percutaneous management of upper urinary tract (UUT) transitional cell carcinoma (TCC) in patients with no history of bladder TCC. PATIENTS AND METHODS: Between 1983 and 2004 we identified 22 patients who underwent endoscopic management of TCC first diagnosed in the UUT and in the setting of a normal contralateral kidney. We performed a retrospective chart review and conducted outcome analyses. RESULTS: The median (range) age at diagnosis was 64 (37-86) years and the median tumour size was 0.8 (0.3-2.6) cm. The tumour grade was 1, 2, or diagnosed as visual low grade in two (9%), seven (32%), and 13 (59%) patients, respectively; no patient ...
Transitional cell carcinoma is cancer of the urothelium, the lining of the urinary tract. In the bladder this cancer is referred to as bladder cancer. When it occurs in the ureter or renal pelvis it is caller upper tract transitional cell carcinoma (UT-TCC). These cancers are rare compared to bladder cancer. In certain instances they can be treated endoscopically with ureteroscopic fulguration or laser ablation. More commonly they require surgical removal. Surgery may precede or follow systemic chemotherapy. When UT-TCC occurs in the lower part of the ureter near the bladder, it may be possible to remove only the affected part of the ureter (distal ureterectomy). Likewise UT-TCC in the middle or upper ureter may possibly be treated with subtotal or total ureterectomy. All these approaches require urinary tract reconstruction consisting of ureteral reimplantation, with or without a psoas hitch, Boari flap, ileal ureter, or autotransplantation of the kidney. When UT-TCC affects the renal pelvis or ...
history of serious or concurrent illness or uncontrolled medical disorder; any medical condition that might be aggravated by treatment or which could not be controlled: active infection requiring antibiotics within 2 weeks before the study inclusion, unstable diabetes mellitus, uncontrolled hypercalcaemia ,2.9 mmol/L (or ,G2 NCI CTCAE v4.0), concurrent congestive heart failure NYHA (class III-IV) or any type of angina pectoris and/or a diagnosis of myocardial infarction during the previous 6 months and/or poorly controlled hypertension will be excluded, QTc ,450 ms at baseline, additional risk factors for Torsade de Pointes (heart failure and hypokalemia (≥G1, i.e. P-K ,LLN-2.5 mM) or family history of long QT-syndrome), cardiac arrhythmias requiring anti-arrhythmics (excluding beta-blockers or digoxin for chronic atrial fibrillation ...
TY - JOUR. T1 - The management of stage T1 grade 3 transitional cell carcinoma of the bladder. AU - Evans, Christopher P. AU - Busby, J. E.. PY - 2003/9. Y1 - 2003/9. KW - BCG. KW - Cystectomy. KW - Superficial bladder cancer. KW - Transitional cell carcinoma. UR - http://www.scopus.com/inward/record.url?scp=0041910054&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=0041910054&partnerID=8YFLogxK. U2 - 10.1046/j.1464-410X.2003.04357.x. DO - 10.1046/j.1464-410X.2003.04357.x. M3 - Article. C2 - 12930415. AN - SCOPUS:0041910054. VL - 92. SP - 345. EP - 348. JO - BJU International. JF - BJU International. SN - 1464-4096. IS - 4. ER - ...
Incidence and Mortality Transitional cell carcinoma of the renal pelvis, accounting for only 7% of all kidney tumors, and transitional cell cancer of the ureter, accounting for only 1 of every 25 upper tract tumors, are curable in more than 90% of patients if they are superficial and confined to the renal pelvis or...
Front-line platinum-based combination chemotherapy leads to high response rates but suboptimum overall survival for patients with advanced transitional-cell carcinoma of the urothelium. Bevacizumab is being assessed in combination with platinum-based first-line chemotherapy in a large phase 3 trial. …
Cytology diagnosis: Malignant, consistent with a high grade metastatic transitional cell carcinoma. Biopsy of same mass diagnosis: Malignant, consistent with a high grade metastatic transitional cell carcinoma. The case was provided by Milstead Pathology, Conyers, GA.. ...
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details ...
A nine-year-old chemically neutered male hovawart was referred due to dysuria, stranguria, haematuria and inappetence. Initial examinations suggested a transitional cell carcinoma of the urinary bladder with pulmonary metastases and ureteral ectopia. To confirm the diagnosis and rule out possible ureteral ectopia, cystoscopy was performed. Transitional cell carcinoma was confirmed, and a urethral foreign body was revealed. After successful removal, the foreign body turned out to be a 17-cm long piece of a urinary catheter. The dogs clinical signs ceased completely a few days after extraction of the foreign object and palliative therapy with meloxicam. Approximately four weeks later its condition deteriorated and the owner elected euthanasia. ...
Highlights: Black-Right-Pointing-Pointer The tumor suppressor gene PDCD4 is down-regulated in many tumorous entities. Black-Right-Pointing-Pointer We investigate the impact of PDCD4 and its regulating factor miR-21 in urothelial carcinoma. Black-Right-Pointing-Pointer We confirm PDCD4 as a tumor suppressor gene and it could be a diagnostic marker for this tumor. -- Abstract: Background: We investigated the role of the programmed cell death 4 (PDCD4) tumor suppressor gene in specimens of transitional cell carcinoma and of healthy individuals. Methods: PDCD4 immunohistochemical expression was investigated in 294 cases in histologically proven transitional cell carcinoma in different tumorous stages (28 controls, 122 non-muscle invasive urothelial carcinoma, stages Tis-T1, 119 invasive transitional cell carcinoma stages T2-T4 and 25 metastases). MiR-21 expression, an important PDCD4 regulator, was assessed with real-time PCR analysis and showed inverse correlation to tissue PDCD4 expression. ...
View details of top transitional cell carcinoma hospitals in Thane. Get guidance from medical experts to select best transitional cell carcinoma hospital in Thane
This report provides comprehensive information on the therapeutic development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.
Transcript of Transitional Cell Carcinoma- What You Need to Know About Your Dogs Cancer. James Jacobson: One of the cancers that you both talk about in the Dog Cancer Survival Guide is transitional cell carcinoma. I wanna first of all throw this to you Dr. Dressler, if youre looking at transitional cell carcinoma, what likely are the signs and symptoms that a dog guardian is facing?. Dr. Demian Dressler: Well, this tumor is most common cancer of the urinary tract that you see more in dogs or in certain breeds like Scottish and also dogs that are more overweight or obese. And the strange thing about transitional cell carcinoma is that its a growth thats coming out from the inside of the bladder wall, growing internally into the bladder, and it can really look like a urinary tract infection to a Veterinarian because the signs are almost identical at least first thought, and those signs reflect inflammation of the bladder with this means to the dog is theyll feel uncomfortable and so many ...
Transitional cell cancer of the renal pelvis and ureter is a disease in which malignant (cancer) cells form in the renal pelvis and ureter. The renal pelvis is the top part of the ureter. The ureter is a long tube that connects the kidney to the bladder. There are two kidneys, one on each side of the backbone, above the...
The Report Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline Review, H2 2014 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz
The recent study by Rosenberg et al in The Lancet-summarized in this issue of The ASCO Post-is a very important paper in the field of bladder cancer therapy.1 It is the first phase II trial in metastatic transitional cell carcinoma that demonstrates the single-agent activity of the investigational programmed cell death ligand 1 (PD-L1) antibody atezolizumab.. Based on objective response rate and low level of toxicity, atezolizumab appears to be superior to all other current single agents used in second-line therapy for transitional cell carcinoma. Moreover, the trial reported by Rosenberg et al strongly confirms the activity of atezolizumab seen in the phase Ib trial of Powles et al.2. Concordant Studies. In the phase Ib trial, patients were initially selected for entry based on PD-L1 expression of 2 to 3+ on the infiltrating immune cells (IC 2/3) in the tumor (not PD-L1 expression on the tumor cells). A subsequent group of patients with IC 0/1 disease were entered on the trial. In the selected ...
Learn more about Transitional Cell Cancer of the Renal Pelvis and Ureter Treatment (PDQ®) (Patients) from the National Cancer Institute at Siteman Cancer Center.
Abstract of Paper: Role of P27 (Kip 1) and MUC1 in Papillary Transitional Cell Carcinoma of the Urinary Bladder , Author: TAGHREED A. ABD EL-AZEEZ, M.D.*; ABD EL-LATEF M. EL-BALSHY, M.D.*, MAGDY EL-TABYE, M.D.** and ADEL Z. ELSAEDY, M.D.* The Departments of Histopathology* and Urosurgery**, Faculty of Medicine, Benha University, Egypt , Year: 2008 , Faculty of Medicine, Benha University
The nested variant of transitional cell carcinoma (TCC-NV) is a rare neoplasm; only eight cases have been described. This report reviews the clinicopathologic features of 16 additional examples. The cases were collected from consultations received during a 13-year period. In most instances, a consultation was sought because the histologic features suggested an atypical proliferation of Brunns nests or a lesion similar to the previously published examples of TCC-NV. Clinical data were gathered and tissues were studied to exclude prostatic cancer and adenocarcinoma. TCC-NV is characterized by the presence of irregular nests and/or tubules of transitional cells infiltrating the lamina propria without surface involvement. Neoplastic cells tend to have innocuous features but at least a few cells in every case are cytologically anaplastic. There is a marked male predominance. Synchronous or metachronous TCCs of more usual histologic make-up may occur. After a follow-up averaging 16.6 months, only three
TY - JOUR. T1 - Germline translocation t(5;20)(p15;q11) and familial transitional cell carcinoma. AU - Schoenberg, Mark. AU - Kiemeney, Lambertus. AU - Walsh, Patrick C.. AU - Griffin, Constance A.. AU - Sidransky, David. PY - 1996/3. Y1 - 1996/3. KW - bladder. KW - carcinoma, transitional cell. KW - heterozygote detection. KW - translocation (genetics). UR - http://www.scopus.com/inward/record.url?scp=0030049893&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=0030049893&partnerID=8YFLogxK. U2 - 10.1016/S0022-5347(01)66380-8. DO - 10.1016/S0022-5347(01)66380-8. M3 - Article. C2 - 8583556. AN - SCOPUS:0030049893. VL - 155. SP - 1035. EP - 1036. JO - Journal of Urology. JF - Journal of Urology. SN - 0022-5347. IS - 3. ER - ...
TY - JOUR. T1 - Transitional cell carcinoma of the prostate. AU - Matzkin, H.. AU - Soloway, M. S.. AU - Hardeman, S.. PY - 1991/1/1. Y1 - 1991/1/1. KW - Carcinoma. KW - Prostatic neoplasms. KW - Transitional cell. UR - http://www.scopus.com/inward/record.url?scp=0026346052&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=0026346052&partnerID=8YFLogxK. U2 - 10.1016/S0022-5347(17)38047-3. DO - 10.1016/S0022-5347(17)38047-3. M3 - Review article. C2 - 1942262. AN - SCOPUS:0026346052. VL - 146. SP - 1207. EP - 1212. JO - Journal of Urology. JF - Journal of Urology. SN - 0022-5347. IS - 5. ER - ...
TY - JOUR. T1 - Transitional cell carcinoma of the upper urinary tract.. AU - Zuckier, L. S.. AU - Kirschenbaum, E. R.. PY - 1989/1. Y1 - 1989/1. UR - http://www.scopus.com/inward/record.url?scp=0024531422&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=0024531422&partnerID=8YFLogxK. U2 - 10.1148/radiology.170.1.2909116. DO - 10.1148/radiology.170.1.2909116. M3 - Letter. C2 - 2909116. AN - SCOPUS:0024531422. VL - 170. SP - 282. EP - 283. JO - Radiology. JF - Radiology. SN - 0033-8419. IS - 1 Pt 1. ER - ...
Transitional cell carcinoma (TCC) of the ureter, also called urothelial cell carcinoma (UCC) of the ureter, are uncommon compared to similar tumors elsewhere along the urinary tract but are nonetheless the most common primary tumor of the ureter....
GARD : 20 The following summary is from Orphanet, a European reference portal for information on rare diseases and orphan drugs. Orpha Number: 284400 Definition Small cell carcinoma of the bladder (SCCB) is a very rare, poorly differentiated neuroendocrine epithelial bladder tumor characterized clinically by hematuria and/or dysuria and a highly aggressive course. Epidemiology SCCB is extremely rare with an annual incidence of less than 1-9/1,000,000. Since 1980, fewer than 1,500 cases have been identified. The demographic profile of SCCB is similar to that of patients with bladder transitional cell carcinoma (TCC). The majority of patients are male, with a mean sex ratio of 5:1, and a range between 1:1 to 16:1. The vast majority of cases were reported in the Caucasian population. Clinical description Most knowledge on SCCB is based on retrospective investigations and on a few prospective studies. Mean age at diagnosis is 67 years (range 32 to 91 years). The clinical features of SCCB are similar ...
BACKGROUND In this study we used histopathological examinations performed over a 20-year period to describe the characteristics of newly diagnosed transitional cell carcinoma (TCC) of the bladder in relation to patient age, and to verify changes in the TCC over different periods of observation or in relation to patient age. METHODS We reviewed all histopathological examinations performed from January 1979 to December 1998 in patients undergoing surgery who were newly diagnosed with TCC of the bladder. All examinations were performed by the same pathologist and reviewed by two pathologists. In each case analyzed, we evaluated T classification of the tumor, histological grade, size, localization, growth type, multiplicity and carcinoma in situ (CIS). RESULTS The study population included 3113 men and 620 women. The mean patient age was 66.31 +/- 10.84 years. A high percentage of Ta (52.2%) and T1 (27.7%) tumors were found. The number of cases observed and, in particular, the percentage of Ta tumors
CT features of multiple lobulated masses projecting into the lumen of the bladder most consistent with a transitional cell carcinoma (pathologically proven).
Transitional Cell Carcinoma, Kidney Cancer Surgery Procedure or Surgery Bearymore - WhatNext.com - Robotic laparascopic radical right nephrectomy.
Trial Specifics. This trial is designed to evaluate the safety and preliminary pain management and effect of a novel therapy in dogs with bladder transitional cell carcinoma (TCC). A secondary goal is to assess potential anti-cancer effect. The trial involves one-time treatment administered directly into the bladder using a urinary catheter. Dogs may receive a second treatment one month after enrollment if warranted. The treatment will be administered under sedation or general anesthesia. There is no placebo in this trial. An estimated 15 client-owned dogs with will be enrolled. Owners will be required to complete quality of life surveys, collect a daily urine sample for visual analysis, and record the urine collection results in a provided journal. The trial site will train the owners on collection and evaluation techniques. Trial visits include the dogs initial consultation, treatment day (Day 0), and then recheck visits on Days 7, 14, 28, 56, and 84. Anti-cancer therapies must be ...
Transitional cell carcinoma is a urinary tract cancer that has a good prognosis if treated early in the disease. Here are the causes, symptoms, diagnosis and treatment.
|b|Objectives:|/b| To determine if detection of cytokeratin 20 (CK20) gene expression, by reverse transcriptase-polymerase chain reaction (RT-PCR) in urine from transitional cell carcinoma
Learn Transitional Cell Carcinoma - Urologic Cancer - Nephrology & Urology for Medicine faster and easier with Picmonics unforgettable videos, stories, and quizzes! Picmonic is research proven to increase your memory retention and test scores. Start learning today for free!
Misdiagnosis of Transitional cell carcinoma including hidden diseases, diagnosis mistakes, alternative diagnoses, differential diagnoses, and misdiagnosis.
Medical Mnemonics - Transitional Cell Carcinoma (TCC) Symptoms & Risks - Urology Mnemonics - Internal Medicine, USMLE Step 3 and USMLE Step 2 questions for the board exam. Free trail!
Treatments for Transitional cell carcinoma including drugs, prescription medications, alternative treatments, surgery, and lifestyle changes.
Video articles in JoVE about t lymphocytes cytotoxic include A Restriction Enzyme Based Cloning Method to Assess the In vitro Replication Capacity of HIV-1 Subtype C Gag-MJ4 Chimeric Viruses, A Colorimetric Assay that Specifically Measures Granzyme B Proteolytic Activity: Hydrolysis of Boc-Ala-Ala-Asp-S-Bzl, Radial Mobility and Cytotoxic Function of Retroviral Replicating Vector Transduced, Non-adherent Alloresponsive T Lymphocytes, Murine Lymphocyte Labeling by 64Cu-Antibody Receptor Targeting for In Vivo Cell Trafficking by PET/CT, Phenotypic and Functional Analysis of Activated Regulatory T Cells Isolated from Chronic Lymphocytic Choriomeningitis Virus-infected Mice, Analysis of Simian Immunodeficiency Virus-specific CD8+ T-cells in Rhesus Macaques by Peptide-MHC-I Tetramer Staining, Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development, A Flow Cytometry-Based Cytotoxicity Assay for the Assessment
abstract = Multiple therapeutic options are available for the management of patients with upper urinary tract transitional cell carcinoma (TCC). Radical nephroureterectomy with an ipsilateral bladder cuff is the gold-standard therapy for upper-tract cancers. However, less invasive alternatives have a role in the treatment of this disease. Endoscopic management of upper-tract TCC is a reasonable strategy for patients with anatomic or functional solitary kidneys, bilateral upper-tract TCC, baseline renal insufficiency, and significant comorbid diseases. Select patients with a normal contralateral kidney who have small, low-grade lesions might also be candidates for endoscopic ablation. Distal ureterectomy is an option for patients with high-grade, invasive, or bulky tumors of the distal ureter not amenable to endoscopic management. In appropriately selected patients, outcomes following distal ureterectomy are similar to that of radical nephroureterectomy. Bladder cancer is a common occurrence ...
OBJECTIVES: To establish whether high microsatellite instability (MSI) (present in almost 20% of cases) and loss of MSH2 protein expression (sometimes used to predict MSI status) are prognostic factors of overall survival for patients with invasive upper urinary tract transitional cell carcinoma (UUT-TCC). UUT-TCC has a poor prognosis (overall survival less than 50% at 5 years). METHODS: The files of 80 patients who underwent nephroureterectomy for invasive UUT-TCC (Stage pT2 or worse) between 1990 and 2002 were reviewed. The following data were collated: age at diagnosis, prior history of cancer, tobacco consumption, tumor stage and grade, and disease progression. MSI was determined by polymerase chain reaction/fragment analysis and MSH2 protein expression by immunohistochemistry on retrieved tumor tissue. RESULTS: The median patient age was 71.5 years. The male/female ratio was 2.8. High MSI and loss of MSH2 expression were encountered in the tumors of 14 (17%) and 21 (26%) of the 80 patients,
For locally advanced or metastatic urothelial carcinoma, cisplatin-based chemotherapy is the standard regimen. Nevertheless, almost all responding patients experience recurrence within the first year. When patients who have received prior cisplatin-based therapy become resistant, combination therapy with gemcitabine and paclitaxel has been reported. Few published case reports have addressed the utility of paclitaxel/cisplatin/gemcitabine combination therapy as second-line chemotherapy for advanced or metastatic urothelial carcinoma. This is the first report describing paclitaxel/cisplatin/gemcitabine combination therapy for metastatic urothelial carcinoma arising in a transplanted renal allograft and leading to a successful outcome. We present a case of metastatic urothelial carcinoma of a renal allograft in a 32-year-old Japanese man with a history of kidney transplantation ten years prior. Because the patients serum creatinine increased, hemodialysis was resumed, and the surgical allograft was
TY - JOUR. T1 - Prospective evaluation of p53 as a prognostic marker in T1 transitional cell carcinoma of the bladder. AU - Dalbagni, Guido. AU - Parekh, Dipen J.. AU - Ben-Porat, Leah. AU - Potenzoni, Michele. AU - Herr, Harry W.. AU - Reuter, Victor E.. N1 - Copyright: Copyright 2008 Elsevier B.V., All rights reserved.. PY - 2007/2. Y1 - 2007/2. N2 - OBJECTIVE: To prospectively evaluate p53 overexpression as a predictor of survival in patients with a first diagnosis of T1 transitional cell carcinoma (TCC) of the bladder, as several reports implicate p53 as an important prognostic marker for progression and survival, but all previous studies were retrospective, giving conflicting and irreproducible results, rendering inappropriate any attempt at integrating p53 into clinical decision-making. PATIENTS AND METHODS: Patients with a first diagnosis of T1 TCC of the bladder were enrolled; p53 overexpression was assessed by immunohistochemistry (IHC) using both monoclonal antibody 1801 and DO7. The ...
Transitional cell carcinoma (TCC) of the female urethra is a rare urological malignancy, and intracranial metastasis of this cancer has not yet been reported in the literature. This review is intended to present a case of multiple intracranial metast
Today, the U.S. Food and Drug Administration (FDA) granted regular approval to pembrolizumab (Keytruda) for patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. The FDA also granted accelerated approval to pembrolizumab for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy.. KEYNOTE-045. The regular approval for the second-line indication was based on data from the KEYNOTE-045 trial, a multicenter, randomized, active-controlled trial in patients with locally advanced or metastatic urothelial carcinoma with disease progression on or after platinum-containing chemotherapy. Patients were randomly assigned (1:1) to receive either pembrolizumab 200 mg every 3 weeks (n = 270) or investigators choice of a chemotherapy regimen (paclitaxel [n ...
The wall of the bladder is lined with several layers of cells called transitional cells. Cancer arising from these cells makes up more than 90% of all bladder cancers and these are referred to as transitional cell carcinomas. Because transitional cell carcinomas are the most common type of bladder cancer, the information in this section only addresses treatment of transitional cell cancer of the bladder. Bladder cancer occurs predominantly in elderly men and less frequently in women and younger men. Many bladder cancers are thought to be caused by exposure to cancer-causing agents that pass through the urine and come into contact with the bladder lining. The most important risk factor for bladder cancer is smoking, which increases risk by at least four-fold.[1]. The most common sign of bladder cancer is hematuria or blood in the urine, which will turn the urine rust or red in color.[2] Other signs of bladder cancer may include pain during urination and frequent urination. Most patients with ...
TY - JOUR. T1 - Metastatic bladder cancer. T2 - Advances in treatment. AU - Stadler, W. M.. AU - Kuzel, T. M.. AU - Raghavan, D.. AU - Levine, E.. AU - Vogelzang, N. J.. AU - Roth, B.. AU - Dorr, F. A.. N1 - Funding Information: Acknowledgements---Studies were supported by research grants from Eli Lilly and Company.. PY - 1997/1. Y1 - 1997/1. N2 - At present, a combination of cisplatin, methotrexate, vinblastine and doxorubicin is the most widely used chemotherapy for metastatic bladder cancer. However, long-term follow up shows that this combination may have little effect on survival. In addition, this regimen is toxic. New agents are needed which combine efficacy with good safety profiles. Agents which have been investigated include gallium nitrate, interferon-α and paclitaxel both as single agents and in combination with established cytotoxic drugs. A number of studies have been conducted in bladder cancer with the novel nucleoside analogue, gemcitabine. Response rates of up to 33% have been ...
TY - JOUR. T1 - A phase I study of enfortumab vedotin in Japanese patients with locally advanced or metastatic urothelial carcinoma. AU - Takahashi, Shunji. AU - Uemura, Motohide. AU - Kimura, Tomokazu. AU - Kawasaki, Yoshihide. AU - Takamoto, Atsushi. AU - Yamaguchi, Akito. AU - Melhem-Bertrandt, Amal. AU - Gartner, Elaina M.. AU - Inoue, Takashi. AU - Akazawa, Rio. AU - Kadokura, Takeshi. AU - Tanikawa, Toshiki. PY - 2019/1/1. Y1 - 2019/1/1. N2 - Locally advanced or metastatic urothelial cancer is an aggressive form of cancer with high recurrence rates and low survival. Nectin-4 is a cell adhesion molecule commonly expressed in several tumors, including high expression in urothelial cancer. Enfortumab vedotin is an antibody-drug conjugate composed of an anti-Nectin-4 humanized monoclonal antibody linked to the microtubule disrupting agent, monomethyl auristatin E. In this phase I study (NCT03070990), Japanese patients with locally advanced/metastatic urothelial cancer treated with prior ...
Background: Transitional cell carcinoma (TCC) originating from the renal pelvis with a venous tumor thrombus is a rare entity. However, clinicians should be aware of it because of its high malignancy and poor prognosis.Case presentationHere, we report three cases of pathologically confirmed TCC originating from the renal pelvis with extension into the renal vein or inferior vena cava (IVC). Of these patients, two are males and one is female (58~73 years old). Their main symptom is flank pain; besides, gross hematuria and weight loss is observed in one of the patients. Computed tomography (CT) scan of the first patient revealed multiple space-occupying lesions in the left renal pelvis and left medium and lower ureter with a tumor thrombus in the left renal vein. CT scan of the second patient revealed a right renal mass and extension into the IVC. Abdominal magnetic resonance imaging (MRI) of the third patient showed a soft tissue mass in the region of the left renal sinus, and the signal of the ...
The transitional cell carcinoma is a particularly unpleasant tumor of the urinary bladder. In dogs, it usually arises in the lower neck of the bladder, where it is virtually impossible to surgically remove, and causes a partial or complete obstruction to urination. Bloody urine and straining to urinate are typically the signs noted by the owner. We know that Shetland sheepdogs, West Highland White terriers, Beagles, and Scottish terriers seem to be predisposed breeds.
Immunocompetence of patients with transitional cell carcinoma as measured by dinitrochlorobenzene skin tests and in vitro lymphocyte function Academic Article ...
durvalumab as second-line therapy for locally advanced or metastatic urothelial carcinoma (UC), NCT01693562, durvalumab provides clinical benefit to patients with locally advanced or metastatic urothelial carcinoma.
In this unique presentation, panelists at the 2019 AUA Annual Meeting cover the management of non-muscle invasive urothelial carcinoma and the management of advanced and metastatic urothelial carcinoma while discussing key take-home messages from AUA2019 sessions.
Advanced/Metastatic Bladder Cancer:. Bellmunt J, Choueiri TK, Fougeray R, Schutz FA, Salhi Y, Winquist E, Culine S, von der Maase H, Vaughn DJ, Rosenberg JE. Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol 2010;28:1850-5.. Bernard-Pierrot I, Brams A, Dunois-Larde C, et al. Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b. Carcinogenesis 2006;27:740-74.. Cancer Genome Atlas Research Network., Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 2014;507:315-22.. Cappellen D, De Oliveira C, Ricol D, et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet 1999;23:18-20.. Chaffer CL, Dopheide B, Savagner P, Thompson EW, Williams ED. Aberrant fibroblast growth factor receptor signaling in bladder and other cancers. Differentiation 2007;75:831-42.. Gómez-Román JJ, Saenz P, ...
TY - JOUR. T1 - Future developments and new research in genitourinary cancers. Perspectives. AU - Alexander, Richard B.. AU - Coffey, Donald S.. PY - 1987/8/1. Y1 - 1987/8/1. N2 - Significant advances in the therapy of genitourinary cancers have occurred, yet the challenge of metastatic disease in many of these tumors remains unsolved. The great success achieved in the treatment of testicular cancer has been in large part due to the development of effective systemic therapy. Effective treatment for metastatic transitional cell carcinoma is just beginning to be described. Advanced renal and prostatic carcinomas remain a major clinical problem with no effective curative therapy. Novel new approaches to systemic therapy developed on sound basic experimental principles are needed. Several potential approaches such as angiogenesis factor, interleukin II, lymphokine activated killer cells, and tumor necrosis factor are discussed.. AB - Significant advances in the therapy of genitourinary cancers have ...
Scottish Terriers are at 18-fold greater risk of developing urinary bladder cancer (invasive transitional cell carcinoma [TCC]) compared with other breeds. TCC is an aggressive tumor, and survival rates are poor. Most TCC of the bladder cannot be removed surgically and is resistant to chemotherapy. The best approach to reduce morbidity and mortality from bladder cancer in Scottish Terriers is to prevent its occurrence. The primary objective this epidemiological study is to identify host (genetic), agent, and environmental factors that increase or decrease the risk of TCC. A case control study is proposed in which Scottish Terriers of comparable ages with or without TCC will be compared. Using medical records and questionnaire responses from owners, the primary risk factors studied will include: (1) exposure to insecticides, particularly the new generation flea control products and lawn chemicals, (2) exposure to side stream cigarette smoke, (3) prior use of cyclooxygenase (cox) inhibiting drugs, a
Accelerated approval was granted to erdafitinib for treating locally advanced or metastatic bladder cancer with genetic alterations FGFR3 or FGFR2 after progressing on chemotherapy. A companion diagnostic was also approved.
New life-saving treatments for Bladder cancer in clinical trial on Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer - Adults
Radiation therapy and concomitant paclitaxel/carboplatin chemotherapy for muscle invasive transitional cell carcinoma of the bladder: a well-tolerated combinati
Phase II trial of gemcitabine [Gemzar], cisplatin, and sunitinib in patients with advanced/metastatic urothelial carcinoma will assess the efficacy and
FDA Approves Mercks KEYTRUDA® (pembrolizumab) for Certain Patients with Locally Advanced or Metastatic Urothelial Carcinoma, a Type of Bladder Cancer
Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study.
Dilatated kidney caused by a transitional carcinoma with a tumor in the ureter and tumor nodules in the renal collecting system CT. ...
An 83-year-old man was diagnosed with multiple low-grade transitional cell carcinomas over a 6-year period. A surveillance cystoscopy in year 7 showed high-grade noninvasive papillary urothelial carcinoma in the bladder trigone. A CT urogram showed a soft-tissue mass with diffuse enhancement in the lower pole of the left kidney, concerning for malignancy.
Transitional cell cancer of the renal pelvis and ureter is a disease in which malignant (cancer) cells form in the renal pelvis and ureter.
and one of the Primary Investigators of the trial. These data support this unique approach to cancer treatment, which aims to improve standard of care therapy by targeting Hsp27, an important mechanism through which cancer develops resistance to treatment.. Apatorsen is designed to inhibit production of heat shock protein 27 (Hsp27), which increases with cancer treatment as well as with tumor stage and grade. High levels of Hsp27 contribute to cancer cell survival, proliferation and migration and also play a role in dampening a cancer patients immune function. Borealis-1 enrolled approximately 180 patients with documented metastatic or locally inoperable transitional cell carcinoma (TCC) of the urinary tract who had not previously received chemotherapy for metastatic disease and were not candidates for potentially curative surgery or radiotherapy. Patients were randomized to receive standard chemotherapy (gemcitabine/cisplatin) in combination with apatorsen at two dose levels (600 mg and 1000 ...
RATIONALE: Vaccines made from peptides may make the body build an immune response to kill tumor cells. Biological therapies, such as BCG and sargramosti
FINAL DIAGNOSIS:. HIGH-GRADE UROTHELIAL CARCINOMA WITH PLASMACYTOID, MICROPAPILLARY AND GLANDULAR DIFFERENTIATION.. DISCUSSION:. This tumor is a poorly differentiated invasive carcinoma, which shows glandular and divergent patterns of differentiation. There is no discrete papillary urothelial carcinoma component or urothelial carcinoma in situ. The tumor shows undifferentiated plasmacytoid histology, glandular differentiation and solid sheet-like architecture (similar to high-grade urothelial carcinoma). Because of the divergent differentiations, the possibility of a metastasis from a primary (like breast or stomach) was considered but was clinically unlikely (with negative mammography and endoscopy). The immunohistochemical profile with the positivity of CK7 and CK20 supports the urothelial origin of this tumor.. A micropapillary variant of transitional cell carcinoma (TCC) was first described in 1994 by Amin et al (1). Four morphological features were described as being distinct to this ...
The clinical impact of salvage surgery after chemotherapy on cancer survival of patients with metastatic urothelial carcinoma is controversial. We aimed to verify the clinical role of salvage surgery by analyzing the long-term outcome in patients with urothelial carcinoma treated by chemotherapy. Between 2003 and 2010 at a single institution, 31 of 47 patients (66%) with metastatic urothelial carcinoma showed objective responses (CR in 4, PR in 27) after multiple courses of cisplatin/gemcitabine/paclitaxel-based chemotherapy, and a cohort of patients with partial response (PR) were retrospectively enrolled. Twelve (10 male and 2 female, median age 64.0 years) of 27 patients with PR underwent salvage surgeries after the chemotherapy: metastatectomy of residual lesions (10 retroperitoneal lymph nodes, 2 lung), and 6 radical surgeries for primary lesions as well. Progression-free survival and overall patient survival rates were analyzed retrospectively and compared with those of patients without ...
Background The typical treatment for patients with advanced transitional cell carcinoma from the bladder is platin structured chemotherapy. tumor specimens of advanced muscle tissue invasive bladder malignancies (T2-4). Using the bladder cell lines T24 and SW780 the relationship of TFAP2 and cisplatin and gemcitabine awareness aswell as cell proliferation was analyzed using siRNA aimed TFAP2 knockdown. Outcomes TFAP2 proteins appearance was analyzed on the TMA with cores from 282 advanced bladder tumor tumors from sufferers treated with cisplatin based combinational chemotherapy. TFAP2 was identified as a strong independent predictive marker for a good response and survival after cisplatin-containing chemotherapy in patients with advanced bladder cancer. Strong TFAP2 nuclear and cytoplasmic staining predicted good response to chemotherapy in patients with lymph node metastasis, whereas weak TFAP2 nuclear staining predicted good response in patients without lymph node metastasis. In vitro studies ...
We have analyzed the methylation pattern of RARβ, DAPK, E-cadherin, p15, p16, MGMT, and GSTP1 in bladder TCC of different stages and grades. In our study, all of our samples have at least one gene methylated, and more than three genes that were methylated accounted for 20% of our cases. Thus, the epigenetic event of gene methylation was frequent in bladder cancer. However, this phenomenon did not appear to be correlated with disease grade or stage.. Reports on the methylation of various genes have been described in primary bladder cancer (12, 13, 14, 15, 16, 17, 18, 19) . Among these reports, methylation of p16 was most commonly investigated. The frequency of p16 methylation in bladder TCC ranged from 9-67% (13, 14, 15, 16, 17 , 19) . Our study represented the largest series and demonstrated p16 methylation of 26.5%. Tumor suppressor gene p16 specifically inactivates cyclin-dependent kinase 4 and cyclin-dependent kinase 6, which interact with cyclin D1 and stimulate the progression of the cell ...
Top 10 cancers for 11759665_a_at (Homo sapiens, Affymetrix Probeset): ovary, granulosa cell tumor, malignant, metastatic, temporal lobe, astrocytoma, NOS, kidney, collecting duct carcinoma, unstated behavior, frontal lobe, mixed glioma, temporal lobe, mixed glioma, skin, basal cell carcinoma, NOS, frontal lobe, oligodendroglioma, NOS, other / unspecified urinary organs, cerebrum, glioblastoma, NOS, renal pelvis, papillary transitional cell carcinoma
The human bladder cancer cell lines, UMUC3 and HT1376, which were used in this study, were purchased from DS Pharma Biomedical (Osaka, Japan). UMUC3 cells were maintained in minimum essential medium (MEM) supplemented with MEM non-essential amino acids (NEAA) and sodium pyruvate (Gibco, St. Louis, MO, USA). HT1376 cells were maintained in RPMI-1640 medium (Wako, Osaka, Japan). Both media were supplemented with 10% FBS (Sigma-Aldrich, St. Louis, MO, USA). The cells were incubated in a humidified incubator at 37°C in an atmosphere of 5% CO2 and 95% air. Each gemcitabine-resistant cell line (GR) was obtained from the parental UMUC3 or HT1376 cells.. The UMUC3 and HT1376 cells were grown in cell culture media containing gemcitabine (Wako), starting with a concentration of 10-2 µM. The cells were then passaged through stepwise increasing concentrations of gemcitabine up to a concentration of 50 µM. The cells were repeatedly passaged at each gemcitabine concentration in the stepwise ...
A 60 years old man with a past history of right renal stone 10 years ago presented with right flank pain for 1 year and gross Hematuria. CT Scan shows right renal mass. Nephrectomy was done. Specimen was subjected for histopathology which confirmed findings of high grade TCC in renal pelvis that extended into renal parenchyma and reach to renal capsule.. ...
The purpose of the study was to evaluate the antitumor activity and the safety of paclitaxel combined with gemcitabine and cisplatin in patients affected by advanced transitional cell carcinoma of the urothelium (TCC). Eighty-five patients affected by advanced TCC and measurable disease were randomized to receive either paclitaxel at dosage of 70 mg/m2, gemcitabine 1000 mg/m2 and cisplatin 35 mg/m2 on days 1 and 8 every 3 weeks (GCP) or gemcitabine 1000 mg/m2 on days 1, 8, 15 and cisplatin 70 mg/m2 on day 2 every 4 weeks (GC). All enrolled patients were considered evaluable for response and toxicity (intention to treat). The observed response rate was 43% for GCP and 44% for GC combination, respectively. Median time to treatment failure was 32 weeks for GCP and 26 weeks for GC and overall survival 61 vs 49 weeks, respectively (p-value not significant). Grade 3-4 neutropenia was observed in 49% of patients treated with GCP vs 35% of those treated with GC (P=0.05) and grade 3-4 thrombocytopenia ...
Gentaur molecular products has all kinds of products like :search , Alpha Dia \ Human Bladder Tumor lysate \ HTL-1325 for more molecular products just contact us
The test has a sensitivity of 90 percent and a specificity of 78 percent. Interference with the test (causing false positives) occurs with marked glucosuria (4+), heavy proteinuria (4+) or pyuria/hematuria (>30-40 WBC or RBC/hpf). Therefore a negative test has an accurate negative predictive value of 95 percent, but a positive test result would mean that further evaluation is indicated to rule-in or rule-out neoplasia ...
Fingerprint Dive into the research topics of Transitional cell carcinoma of the ureteral stump 23 years after radical nephrectomy for adenocarcinoma. Together they form a unique fingerprint. ...
Prof Arlene Siefker-Radtke talks about the data presented at ASCO GU 2019 and the potential impact on treatment landscape in metastatic urothelial cancer.
In the United States, there are millions more owned cats than owned dogs, yet cats visit veterinarians less frequently than dogs. A major reason is that it is very stressful to take cats to the veterinary practice and often owners believe their cat doesnt need routine check-ups for wellness and preventive care. The Cat Friendly Practice® (CFP) program, created by expert feline practitioners, provides a solution to this trend and provides an opportunity for veterinary practices to elevate care for cats and reduce the stress during the visit ...
Urothelial bladder cancer is estimated to cause 165,084 annual deaths worldwide including over 15,960 in the United States. Outcomes for metastatic urothelial cancer remain poor with an overall 5-year survival rate of 15%, despite modern chemotherapy regimens. Recently, five antiPD-1/PD-L1 antibodies were approved between 2016 and 2017, which reignited immunotherapeutic development in bladder cancer. Despite the impressive activity of these drugs, including many patients with complete responses, the objective response rates remain only 15- 20%. Thus, the majority of patients with bladder cancer still fail to respond to immunotherapy.. Responsiveness to immune checkpoint inhibitors such as anti-PD-1/PD-L1 therapy is dependent on the presence of a preexisting immune infiltrate, also referred to as the T cell-inflamed phenotype. Our recent analysis of muscle invasive bladder cancer has indicated that the majority of bladder cancers lack a T cell-inflamed tumor microenvironment, as measured by ...
In the present study we demonstrated for the first time that, Pim-1 was increased in human bladder cancer epithelium as compared with that in normal bladder tissue. When the tumors were stratified by Non-invasive and invasive, a statistically significant increase of Pim-1 expression was found in the subgroup of invasive tumor when compared with that in the Non-invasive tumor. Pim-1 was also detected in all human bladder cancer cell lines tested in our study. Knockdown Pim-1 led to decreased phosphorylation of Bad and reduced expression of Bcl-2. Furthermore, downregulation of Pim-1 inhibited the bladder cancer cells growth and sensitized them to chemotherapy in vitro. Further evaluation of the prognostic significance of Pim-1 in a larger cohort with sufficient follow-up times will allow better understand of the clinical significance of Pim-1.. Overexpression of the Pim-1 protein has been reported in hematolymphoid malignancies and solid cancers [4, 5]. Pim-1 has been asserted to promote ...

No data available that match "carcinoma transitional cell"

... squamous cell, transitional cell carcinomas, adenosquamous of the rectum Moderator: mp327 Subforum: Archived Posts 2006-2010 ... signet ring cell, spindle cell, transitional cell, translocation cell) renal sarcoma, and wilms tumor 39 Topics. 235 Posts. ... carcinoma (chromophobe renal cell, collecting duct, medullary renal cell, mucinous tubular, rhabdoid tumor, sarcomatoid, ... Acinic Cell Carcinoma. 36 Topics. 404 Posts. Last post. by smartis Sat Nov 07, 2020 11:45 pm ...
  • Transitional cell carcinomas arise from the transitional epithelium, a tissue lining the inner surface of these hollow organs. (wikipedia.org)
  • Transitional cell carcinoma has its origin at the level of the periurethral ducts in the area of the junction of the cylindrical and transitional epithelium. (nih.gov)
  • A malignant neoplasm derived from transitional epithelium, occurring chiefly in the urinary bladder, ureters or renal pelves (especially if well differentiated), frequently papillary. (jove.com)
  • Transitional cell carcinoma (TCC) is a malignant (aggressive) and metastasizing (spreading) cancer arising from the transitional epithelium - the highly stretchable lining of the urinary tract system - of the kidney, ureters (the tubes that carry fluid from the kidneys to the bladder), urinary bladder, urethra (the tube that carries urine from the bladder to the outside), prostate, or vagina. (petmd.com)
  • Normal transitional cell epithelium was negative or stained with weak intensity ( B , pre-adsorption control using an antigenic peptide). (nih.gov)
  • 12 A transitional cell carcinoma that has sarcoma-like components arising from the malignant transitional epithelium. (malacards.org)
  • This study sought to establish whether cytokeratin (CK) 14, normally expressed in the basal cells of squamous epithelium, could be used as a reliable marker of the emergence of a squamous phenotype in transitional cell carcinomas. (bmj.com)
  • Bladder cancer usually starts in the transitional epithelium, the cells that line the bladder. (medicalnewstoday.com)
  • The pattern of growth of transitional cell carcinomas can be papillary, sessile, or carcinoma in situ. (wikipedia.org)
  • Transitional cell carcinomas are mostly papillary (70%, and 30% non-papillary). (wikipedia.org)
  • The 1973 WHO grading system for transitional cell carcinomas (papilloma, G1, G2 or G3) is most commonly used despite being superseded by the 2004 WHO grading for papillary types (papillary neoplasm of low malignant potential [PNLMP], low grade, and high grade papillary carcinoma). (wikipedia.org)
  • Papillary transitional cell carcinoma, low grade Histopathology of urothelial carcinoma of the urinary bladder, showing a nested pattern of invasion. (wikipedia.org)
  • Papillary transitional cell carcinomas (T a tumors) are often multifocal and only occasionally progress, whereas flat tumors (carcinomas in situ , CIS), frequently progress to invasive disease. (aacrjournals.org)
  • Ribeiro-Silva A. Immunohistochemical features of a papillary squamous cell carcinoma of the endometrium with transitional cell differentiation. (termedia.pl)
  • Hydronephrosis on preoperative axial CT at the time of diagnosis of upper-tract urothelial carcinoma is associated with advanced-stage cancer and is a predictor of poorer outcomes. (medscape.com)
  • Transitional cell carcinoma, also called urothelial carcinoma, is a type of cancer that typically occurs in the urinary system. (wikipedia.org)
  • Signs and symptoms of transitional cell carcinomas depend on the location and extent of the cancer. (wikipedia.org)
  • Transitional cell carcinoma of the ovary (TCC of the ovary) is a rare type of ovarian cancer that has an appearance similar to urothelial carcinoma (also known as transitional cell carcinoma). (wikipedia.org)
  • Urothelial carcinoma (formerly known as transitional cell carcinoma) is a cancer involving parts of the kidney, bladder and ureter (the tube that connects the kidney to the bladder). (nyp.org)
  • Specifically, the cancer develops in the cells that line the bladder, ureter or renal pelvis (the part of the kidney that connects to the ureter, and collects and drains urine). (nyp.org)
  • Misuse and long-term use of certain over the counter pain medicines is suspected of increasing the risk of developing transitional cell cancer as well. (nyp.org)
  • People with urothelial carcinoma of the kidney often have the same symptoms as patients with renal cell cancer. (nyp.org)
  • [ 3 ] Individuals with a history of bladder cancer are at risk for upper tract recurrence, with a further increase in patients with carcinoma in situ (CIS) (rather than patients with superficial TCC) and in patients treated with cystectomy for CIS (rather than for invasive bladder cancer). (medscape.com)
  • Erlotinib hydrochloride is FDA approved and commercially available for the treatment of non-small cell lung cancer and pancreatic cancer. (knowcancer.com)
  • Transitional cell carcinoma (TCC) is the most common type of bladder cancer in dogs. (upenn.edu)
  • Recent studies suggest that expression of cyclooxygenase-2 (Cox-2) is elevated in transitional cell carcinoma (TCC) of the urinary bladder and that inhibition of Cox-2 activity suppresses bladder cancer in experimental animal models. (nih.gov)
  • We have developed an orthotopic organ culture model of bladder cancer in which quantum dot-based fluorescent imaging approaches are used to obtain quantitative measurements of tumor cell behavior. (aacrjournals.org)
  • Using this approach, we compared the growth and invasion of the TCCSUP and 253J-BV bladder cancer cell lines. (aacrjournals.org)
  • Thus, we were able to assign distinct phenotypes to two metastatic bladder cancer cell lines based on different patterns of invasiveness into the bladder wall. (aacrjournals.org)
  • I was told that there is a 50% chance of the cancer returning, most likely in the bladder since it has the same kind of cells in the lining of the organ. (cancer.org)
  • Cabazitaxel is a new taxane, taxanes have demonstrated activity in advanced bladder cancer, and are among the most active new cytotoxic agents to be assessed in transitional cell carcinoma. (knowcancer.com)
  • Transitional Cell Carcinoma (TCC) is a cancer of the dog's urinary tract: bladder, ureters, urethra, or prostate gland. (dogcancerblog.com)
  • The most common type of bladder cancer is called transitional cell carcinoma (TCC). (verywellhealth.com)
  • Many cases of suspected prostate cancer in dogs may actually be transitional cell carcinoma (TCC) of the urethra that is metastatic to the prostate. (caninecancerawareness.org)
  • Management of transitional cell carcinoma (TCC) depends upon the site of the cancer (bladder, ureter, renal pelvis), the stage of the disease(extent of spread), and the pathological grading of the tumor. (rightdiagnosis.com)
  • BACKGROUND: Transitional cell carcinoma (TCC) of the female urethra is a rare urological malignancy, and intracranial metastasis of this cancer has not yet been reported in the literature. (biomedsearch.com)
  • Transitional cell carcinoma is a very rare histological subtype of endometrial cancer, with only 18 cases described in literature. (termedia.pl)
  • Bonner RB, Hemstreet GP, Fradent Y, Rao JY, Min KW, Hurst RE: Bladder cancer risk assessment with quantitative fluorescence image analysis of tumor markers in exfoliated bladder cells. (karger.com)
  • Transitional cell carcinoma (TCC) represented 90% of all the bladder cancer cases diagnosed in the USA [2]. (termedia.pl)
  • Although some achievements in chemotherapy regimens improved the therapies of bladder cancer, the 5-year survival rate of bladder transitional cell carcinoma (BTCC) patients still ranges from 48 to 66% [3]. (termedia.pl)
  • Autophagy serves an essential role in maintaining tissue homeostasis to support cell growth and survival [4], such as inflammatory bowel disease, neuronal degeneration, aging and cancer. (termedia.pl)
  • Given these findings, we hypothesized that DRAM2 mediates chemoresistance in bladder cancer cells. (termedia.pl)
  • RT112 bladder cancer cells, endogenously expressing CYP1A1, were selectively chemosensitive to ICT2700, whereas EJ138 bladder cells which do not express CYP1A1 were significantly less responsive. (aacrjournals.org)
  • Transitional cell carcinoma (TCC), the most common cancer of the urinary bladder in dogs, is usually diagnosed at an advanced disease stage with limited response to chemotherapy. (oregonstate.edu)
  • The informativeness of these expression profiles and the high frequency of tumor cell exfoliation into urine have raised the prospect of using simple gene expression signatures obtained from urine total RNA to better diagnose bladder cancer and provide more information on disease characteristics at the time of diagnosis. (aacrjournals.org)
  • Transitional cell carcinoma (TCC), also termed urothelial cell carcinoma, is the most common type of bladder cancer in the United States. (spandidos-publications.com)
  • It is known that patients with bladder cancer have mutations in cell cycle checkpoint genes that are associated with malignant growth and genetic instability. (spandidos-publications.com)
  • Several previous studies on cell cycle regulation and bladder cancer genetics have demonstrated that the overexpression of cyclin D1 and Cdk4/6 and high levels of phosphorylation of Rb contribute to the dysregulation of the cell cycle during oncogenesis and tumor progression in bladder cancer ( 4 - 6 ). (spandidos-publications.com)
  • Methotrexate, vinblastine, doxorubicin and cisplatin for advanced transitional cell cancer of the urothelium. (springermedizin.de)
  • Urinary bladder carcinoma is estimated to be the ninth most common cause of cancer worldwide. (eurekaselect.com)
  • Rony Benson, Supriya Mallick, K.P. Haresh, P.K. Julka and G.K. Rath, "Radiotherapy in Transitional Cell Carcinoma of Urinary Bladder Cancer -Where Does it Fit Into Treatment Protocol", Current Cancer Therapy Reviews (2015) 11: 94. (eurekaselect.com)
  • Transitional cell carcinoma (TCC) accounts for around 95% of bladder cancers and is the 4th most common cancer among men and the tenth most common in women, in the US. (biomedcentral.com)
  • Transitional cell carcinoma (TCC) is a malignant cancer that originates from the transitional epithelial cells of the urinary tract. (biomedcentral.com)
  • Invasive Bladder Transitional Cell Carcinoma, also known as infiltrating bladder urothelial carcinoma , is related to non-invasive bladder urothelial carcinoma and transitional cell carcinoma , and has symptoms including dysuria An important gene associated with Invasive Bladder Transitional Cell Carcinoma is RBX1 (Ring-Box 1), and among its related pathways/superpathways are Pathways in cancer and TGF-beta Signaling Pathway (WikiPathways) . (malacards.org)
  • Procedure or Surgery Associated with Transitional Cell Carcinoma, Kidney Cancer. (whatnext.com)
  • Read more Transitional Cell Carcinoma, Kidney Cancer experiences about Surgery . (whatnext.com)
  • Read and answer Transitional Cell Carcinoma, Kidney Cancer questions . (whatnext.com)
  • Photomicrograph showing transitional cell bladder cancer with densely packed malignant cells (hematoxylineosin, X240). (jamanetwork.com)
  • In bladder cancer, cancerous cells develop in the organ that collects urine from the kidneys before eliminating it from the body through urination. (medicalnewstoday.com)
  • Bladder cancer happens when abnormal cells develop in the bladder. (medicalnewstoday.com)
  • There are different types of bladder cancer, but most cases are urothelial, or transitional cell carcinoma (TCC). (medicalnewstoday.com)
  • Does prostate transitional cell carcinoma preclude orthotopic bladder reconstruction after radical cystoprostatectomy for bladder cancer? (duke.edu)
  • Other types are squamous cell carcinoma, adenocarcinoma, and sarcoma. (oncologynurseadvisor.com)
  • The tough cells that make up the skin are called "squamous" epithelial cells because of their flat overlapping, scale-like design which helps them form a barrier similar to the shingles of a roof-top. (marvistavet.com)
  • Cytokeratin 14 as a marker of squamous differentiation in transitional cell carcinomas. (bmj.com)
  • The presence of squamous differentiation in transitional cell carcinomas has been variably related to prognosis and response to radiotherapy. (bmj.com)
  • The most common histological subtype of diverticulum tumors is transitional cell carcinoma (TCC). (urotoday.com)
  • As a result of this development, tumors of the renal collecting system have cell origins different from those of the renal parenchyma. (medscape.com)
  • Upper urinary tract transitional cell carcinomas (TCCs) are relatively rare, accounting for 5-7% of all renal tumors and 5% of all urothelial tumors. (medscape.com)
  • Taken together, our data suggest that Cox-2 is highly expressed in noninvasive bladder carcinomas, whereas the highest expression of invasive tumors associated with the invading cells, and that Cox-2 may also have a pathophysiological role in nonneoplastic conditions of the urinary bladder, such as ulcerations and inflammatory pseudotumors. (nih.gov)
  • As a boarded oncologist, I see not only the common cancers in dogs like lymphoma, mast cell tumors, osteosarcomas, hemangiosarcomas, and mammary cancers. (dogcancerblog.com)
  • Transitional cell carcinoma ( TCC ) of the ureter, also called urothelial cell carcinoma ( UCC ) of the ureter, are uncommon compared to similar tumors elsewhere along the urinary tract but are nonetheless the most common primary tumor of the ureter. (radiopaedia.org)
  • Transitional cell carcinomas (TCC) are the most common malignant tumors of the canine urinary tract. (laboklin.co.uk)
  • RNA markers with high overexpression in stage Ta tumors and/or T1 to T4 tumors but low expression in blood or inflammatory cells were characterized by quantitative reverse transcription-PCR using 2 mL of voided urine from 75 TCC patients and 77 control patients with other urological diseases. (aacrjournals.org)
  • In contrast, tumors that have not invaded the muscularis propria (stage Ta, T1, and in situ carcinomas) are usually resected by organ-preserving transurethral resection and present 10-year survival rates of 70% to 85% ( 2 ). (aacrjournals.org)
  • Transitional cell carcinoma arises from the epithelial layer found in the renal pelvis, ureter, or bladder. (oncologynurseadvisor.com)
  • on Oct.11th I had surgery and he did do a full radical nephroureterectomy.Said bladder and other kidney and ureter looked good.My pathology results were grade 3 transitional cell carcinoma. (cancer.org)
  • The previously seen intravesical lesion at the right posterolateral wall at the right vesicoureteric junction demonstrated strong diffusion restriction at B value 1200 indicating a malignant tumor with invasion of the wall of the bladder from outside suggesting that the tumor is at the end of the right ureter, mostly transitional tumor. (radiopaedia.org)
  • The ureter is the least common location for transitional cell carcinoma (TCC) of the urinary tract, 2-3 times less common that TCC of the renal pelvis and 100 times less common that transitional cell carcinoma of the bladder. (radiopaedia.org)
  • Ultrasound has little role to play in the diagnosis of transitional cell carcinoma of the ureter, although it may suggest the diagnosis by diagnosing hydronephrosis . (radiopaedia.org)
  • Conventional CT with or with contrast medium often struggle to diagnose a small ureteral transitional cell carcinoma as all that may be visible is focal soft tissue thickening of the ureter. (radiopaedia.org)
  • 1. Leder RA, Dunnick NR. Transitional cell carcinoma of the pelvicalices and ureter. (radiopaedia.org)
  • The technique allows the surgeon to perform an en bloc resection of the kidney, ureter, and bladder cuff without compromising oncologic principles. (eurekamag.com)
  • Patients with locally advanced or metastatic transitional cell carcinoma of the bladder, ureter or renal pelvis were eligible for this study. (biomedcentral.com)
  • First-line chemotherapy regimens for advanced or metastatic transitional cell carcinomas consists of gemcitabine and cisplatin) or a combination of methotrexate, vinblastine, adriamycin, and cisplatin. (wikipedia.org)
  • Cabazitaxel in Platinum Pre-treated Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma Who Developed Disease Progression Within 12 Months of Platinum Based Chemotherapy. (knowcancer.com)
  • The study aims to compare the overall response rate of cabazitaxel treatment versus best supportive care including single agent chemotherapy in patients with locally advanced or metastatic transitional cell carcinoma who developed disease progression within 12 months of platinum based chemotherapy. (isrctn.com)
  • Only after the pathology results come back did they realize it was transitional cell. (cancer.org)
  • Patients with histology/cytology confirmed Transitional Cell Carcinoma (TCC) including mixed pathology with predominantly TCC, with locally advanced (T4b) or metastatic (lymph node or visceral) TCC arising from bladder or upper urinary tracts. (knowcancer.com)
  • Histopathology was mapped to a mucosal photograph of each stomach, enabling precise localisation of carcinoma foci, benign pathology, and mucosal zones. (bmj.com)
  • Of the 17 patients (35%) 6 had transitional cell carcinoma prostatic involvement (carcinoma in situ in 4 and stromal invasion in 2), and 5 of these 6 died, none with or of urethral recurrence but of the primary bladder pathology. (duke.edu)
  • How are transitional cell carcinomas (TCCs) staged? (medscape.com)
  • Most are transitional cell carcinomas (TCCs), which are also called urothelial carcinomas. (medscape.com)
  • We have investigated the expression of Cox-2 protein in human TCCs (n = 85), in in situ carcinomas (Tis) of the urinary bladder (n = 17), and in nonneoplastic urinary bladder samples (n = 16) using immunohistochemistry. (nih.gov)
  • However, several invasive TCCs exhibited the strongest intensity of Cox-2 staining in the invading cells, whereas other parts of the tumor were virtually negative. (nih.gov)
  • Epidemiology of transitional cell carcinomas of the renal pelvis are similar to those of the rest of the urinary tract: please refer to TCCs of urinary tract for further details. (radiopaedia.org)
  • When the term "urothelial" is used, it specifically refers to a carcinoma of the urothelium, meaning a transitional cell carcinomas of the urinary system. (wikipedia.org)
  • Front-line platinum-based combination chemotherapy leads to high response rates but suboptimum overall survival for patients with advanced transitional-cell carcinoma of the urothelium. (nih.gov)
  • RNA was extracted from cells collected from the urine and RT-PCR was performed with specific primers for the amplification of cytokeratin 8, a general marker for epithelial cells, and of CK 20, a marker for TCC urothelium. (karger.com)
  • We hypothesized that mRNAs with high overexpression in transitional cell carcinomas (TCC) compared with normal urothelium and low expression in blood and inflammatory cells would constitute sensitive urine markers that also showed high specificity in patients presenting with hematuria or urinary tract infections. (aacrjournals.org)
  • This is the first study that evaluated the role of anthracyclines in combination with paclitaxel as second-line chemotherapy in metastatic transitional cell carcinoma of the urothelium. (springermedizin.de)
  • Recent studies have demonstrated the effectiveness of cisplatin-based combinations in patients with advanced transitional cell carcinoma(TCC) of the urothelium. (biomedcentral.com)
  • The aim of the study was to evaluate the activity and tolerability of gemcitabine plus carboplatin combination as first-line treatment in patients with advanced transitional cell carcinoma of the urothelium. (biomedcentral.com)
  • On the basis of these considerations, we conducted a single-arm phase II study to evaluate the objective response rate and tolerability of the combination of gemcitabine and carboplatin in Chinese patients with advanced transitional cell carcinoma of the urothelium. (biomedcentral.com)
  • Cox-2 positivity in an invasive (T3) carcinoma, whereas normal transitional cell epithelial cells ( asterisks ) remained essentially negative. (nih.gov)
  • Epithelial cells are cells that line areas of the body that interface with the outside environment. (marvistavet.com)
  • There are many different types of epithelial cells depending on the immediate environment they contact. (marvistavet.com)
  • The epithelial cells of the respiratory tract secrete lubricant but also are designed to trap inhaled particles in secreted mucus and use tiny hair-like "cilia" to push them out of the lower tract and back upward where they can be coughed up. (marvistavet.com)
  • These are called "ciliated" columnar epithelial cells. (marvistavet.com)
  • 1 E-cadherin is a member of the cadherin family of homophilic cell adhesion proteins that are central to the processes of development, cell differentiation, and maintenance of epithelial architecture. (bmj.com)
  • 2 It is the predominant cadherin family member expressed in epithelial tissue and is localised at the adherens junctions on the basolateral surface of the cell. (bmj.com)
  • Sarcomatoid Transitional Cell Carcinoma, also known as transitional cell carcinoma, spindle cell , is related to kidney pelvis sarcomatoid transitional cell carcinoma and transitional cell carcinoma . (malacards.org)
  • Diagnostic, clinical and therapeutic aspects of primary transitional cell carcinoma of the prostate]. (nih.gov)
  • Intracranial metastasis from primary transitional cell carcinoma of female urethra: case report & review of the literature. (biomedsearch.com)
  • Treatment for localized stage transitional cell carcinomas is surgical resection of the tumor, but recurrence is common. (wikipedia.org)
  • Transitional cell carcinomas are graded 1 to 3 or 4 according to the degree of anaplasia, grade 1 appearing histologically benign but being liable to recurrence. (jove.com)
  • PURPOSE: We determined if urethral preservation and orthotopic bladder replacement in patients with transitional cell carcinoma within the prostatic urethra or prostate placed these patients at risk for urethral recurrence or death. (duke.edu)
  • Of the 70 patients 17 had disease recurrence (13 died of disease and 4 are alive, 1 of whom had urethral recurrence without initial prostatic transitional cell carcinoma). (duke.edu)
  • Of these 5 patients 1 had stromal invasive transitional cell carcinoma of the prostate and experienced a bulbar urethra recurrence at 1 month and a pelvic recurrence at 3 months, and died at 5 months. (duke.edu)
  • Thus, of the 14 patients who had prostatic transitional cell carcinoma, only 1 had urethral recurrence (7%), and this recurrence did not present as the cause of death. (duke.edu)
  • Evans, CP & Busby, JE 2003, ' The management of stage T1 grade 3 transitional cell carcinoma of the bladder ', BJU International , vol. 92, no. 4, pp. 345-348. (elsevier.com)
  • The nested variant of transitional cell carcinoma: an aggressive neoplasm with innocuous histology. (semanticscholar.org)
  • For these reasons the authors conducted a series of experiments designed to explore the possible therapeutic effects of AS in the MBT2 murine bladder carcinoma model. (chiro.org)
  • This report provides comprehensive information on the therapeutic development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. (pitchengine.com)
  • It also reviews key players involved in the therapeutic development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma) and special features on late-stage and discontinued projects. (pitchengine.com)
  • Lamm describes a success story in oncology that he helped create, namely, the favorable therapeutic effect of intravesical bacillus Calmette-Guérin (BCG) against carcinoma in situ (CIS) of the bladder. (cancernetwork.com)
  • In order to improve the therapeutic efficacy of BTCC, it is urgent to advance our understanding of mechanisms for gemcitabine-induced resistance and increase tumor cell sensitivity to gemcitabine [7]. (termedia.pl)
  • Multiple therapeutic options are available for the management of patients with upper urinary tract transitional cell carcinoma (TCC). (elsevier.com)
  • Our findings show the substantial activity of weekly regimen of paclitaxel and epirubicin: due to its manageable profile of toxicity, this schedule could represent an interesting therapeutic option in previously treated patients with advanced urothelial carcinoma. (springermedizin.de)
  • Histopathology of urothelial carcinoma of the urinary bladder. (wikipedia.org)
  • Histopathology revealed transitional cell carcinoma in a urachal cyst. (elsevier.com)
  • This group may include any patient requiring cystectomy, including patients with recurrent or extensive superficial disease (cTa-T1N0M0), CIS (carcinoma in situ), or muscle invasive disease (cT2-3aN0M0), whose tumor could not be completely removed at transurethral resection. (knowcancer.com)
  • Invasive (T1) carcinoma ( H , the pre-adsorption control). (nih.gov)
  • Although long-term followup data are not yet available, it appears that laparoscopic radical nephroureterectomy may supplant open surgery as the standard of care in patients with muscle invasive or high grade upper tract transitional cell carcinoma. (nih.gov)
  • Clinical evaluation of mitoxantrone and piroxicam in a canine model of human invasive urinary bladder carcinoma. (dogcancerblog.com)
  • A rare (less than 0.3% of invasive bladder tumours), deceptively bland yet clinically aggressive urothelial carcinoma, which affects older people, especially males. (thefreedictionary.com)
  • Prognostic value of lymph node dissection in patients with muscle-invasive transitional cell carcinoma of the upper urinary tract. (semanticscholar.org)
  • OBJECTIVES To analyze the prognostic role of lymphadenectomy (LND) in patients with muscle-invasive transitional cell carcinoma (TCC) of the upper urinary tract (UUT) managed with radical surgery. (semanticscholar.org)
  • Eight of these 53 patients (15%) had prostatic involvement (carcinoma in situ in 6, intraductal carcinoma in 1 and stromal invasive transitional cell carcinoma in 1). (duke.edu)
  • Transitional cell carcinomas are often multifocal, with 30-40% of patients having more than one tumor at diagnosis. (wikipedia.org)
  • Transitional cell carcinoma of the bladder, the second most common urologic malignancy, is amenable to early diagnosis. (urotoday.com)
  • When checking for a misdiagnosis of Transitional cell carcinoma or confirming a diagnosis of Transitional cell carcinoma, it is useful to consider what other medical conditions might be possible misdiagnoses or other alternative conditions relevant to diagnosis. (rightdiagnosis.com)
  • Despite NVUCs' low-grade histology, they are bad actors which, given the typical delay in diagnosis, contributes to their more advanced local stage compared to conventional high-grade urothelial carcinoma. (thefreedictionary.com)
  • My 13 year old Gracie got a diagnosis this week of transitional cell carcinoma. (dolforums.com.au)
  • RT-PCR with ODF4 , MAGEA3 , and MAGEAB4 on urinary exfoliated cells could provide clinicians with a promising method to improve TCC diagnosis, especially in the case of gross hematuria and catheterization. (ac.ir)
  • Pathological examination of the resected mass revealed a metastatic carcinoma from a known urethral TCC. (biomedsearch.com)
  • In their extensive review of metastatic carcinoma in the skin, Brownstein and Helwig3 did not mention such a case. (jamanetwork.com)
  • Urothelial carcinoma of the kidney is highly curable, if found early. (nyp.org)
  • He had undergone a radical cystectomy with neobladder construction for transitional cell carcinoma of the urinary bladder seven months previously and had received five cycles of adjuvant dose-dense MVAC (Methotrexate, Vinblastine, Adriamycin, and Cisplatin) chemotherapy after the operation. (hindawi.com)
  • Outcomes following radical cystectomy for nested variant of urothelial carcinoma: a matched cohort analysis. (semanticscholar.org)
  • Noninvasive (Ta) carcinoma ( F , the pre-adsorption control). (nih.gov)
  • Noninvasive transitional cell carcinomas of the bladder can have two distinct morphologies suggesting they contain different genetic alterations. (aacrjournals.org)
  • To determine if detection of cytokeratin 20 (CK20) gene expression, by reverse transcriptase-polymerase chain reaction (RT-PCR) in urine from transitional cell carcinoma (TCC) patients, can provide a new noninvasive tool for the follow-up of patients with urothelial carcinoma of the bladder. (karger.com)
  • CK20 detection in urine cells is a simple, noninvasive method with a high potential to become the marker of choice for monitoring and follow-up of TCC patients. (karger.com)
  • There are 3 clinical trials for primary peritoneal transitional cell carcinoma, of which 3 are open and 0 are completed or closed. (mycancergenome.org)
  • Nedisertib, nilotinib, and oncolytic measles virus encoding thyroidal sodium iodide symporter are the most common interventions in primary peritoneal transitional cell carcinoma clinical trials. (mycancergenome.org)
  • Radiographic appearance of pulmonary metastases from transitional cell carcinoma of the bladder and urethra of the dog. (dogcancerblog.com)
  • Methods and Materials: Data for 33 patients receiving WBRT alone for multiple brain metastases from transitional cell bladder carcinoma were retrospectively analyzed. (elsevier.com)
  • McDonald et al2 found only two cases of cutaneous metastases in 1,114 cases of primary bladder carcinoma. (jamanetwork.com)
  • We know that female dogs tend to get more transitional cell carcinomas than male dogs (possibly because females do less urine marking and are thus possibly storing urinary toxins longer). (marvistavet.com)
  • Evaluation of a bladder tumor antigen test as a screening test for transitional cell carcinoma of the lower urinary tract in dogs. (dogcancerblog.com)
  • Herbicide exposure and the risk of transitional cell carcinoma of the urinary bladder in Scottish terrier dogs. (dogcancerblog.com)
  • Piroxicam therapy in 34 dogs with transitional cell carcinoma of the urinary bladder. (dogcancerblog.com)
  • Piroxicam, mitoxantrone, and course fraction radiotherapy for the treatment of transitional cell carcinoma of the bladder in 10 dogs: a pilot study. (dogcancerblog.com)
  • Evaluation of carbon dioxide laser ablation combined with mitoxantrone and piroxicam treatment in dogs with transitional cell carcinoma. (dogcancerblog.com)
  • Transitional cell carcinoma (TCC) is the most common urinary tract tumor in dogs and research suggests that it may becoming more common. (vetcontact.com)
  • We evaluated the use of Laparoscopically Implanted Tissue Expander Radiotherapy (LITE-RT) to exclude critical structures during irradiation of the urinary bladder in two dogs with transitional cell carcinoma (TCC) using helical tomotherapy. (avmi.net)
  • Anatomical templates of lymph node dissection for upper tract urothelial carcinoma: a systematic review of the literature. (urotoday.com)
  • Indications and techniques of lymph node dissection (LND) for upper tract urothelial carcinoma (UTUC) are still controversial. (urotoday.com)
  • Are the Formulas Used to Estimate Renal Function Adequate for Patients Treated With Cisplatin-Based Chemotherapy After Nephroureterectomy for Upper Tract Urothelial Carcinoma? (urotoday.com)
  • The relationship between endogenous creatinine clearance (eCrCl) and renal function values obtained using mathematical formulas has not yet been fully elucidated, especially in patients with upper tract urothelial carcinoma that are treated with radical nephroureterectomy followed by cisplatin-based chemotherapy. (urotoday.com)
  • Systematic regional lymph node dissection for upper tract urothelial carcinoma improves patient survival. (semanticscholar.org)
  • Lymph node yield and tumor location in patients with upper tract urothelial carcinoma undergoing nephroureterectomy affects survival: A U.S. population-based analysis (2004-2012). (semanticscholar.org)
  • Ureteral Involvement Is Associated with Poor Prognosis in Upper Urinary Tract Urothelial Carcinoma Patients Treated by Nephroureterectomy: A Multicenter Database Study. (semanticscholar.org)
  • Why are upper tract urothelial carcinoma two different diseases? (semanticscholar.org)
  • Evidenced-based clinical practice guideline for upper tract urothelial carcinoma (summary--Japanese Urological Association, 2014 edition). (semanticscholar.org)
  • Erlotinib hydrochloride is designed to block the activity of a protein found on the surface of many tumor cells that may control tumor growth and survival. (knowcancer.com)
  • To estimate the depth of invasion of Qdot-labeled tumor cells into the bladder wall, we employed TPLSM. (aacrjournals.org)
  • Measurement of fluorescent signals from both tumor cells and the surrounding tissue enabled evaluation not only of the size of tumor foci, but also the extent of tumor cell invasion into the bladder wall. (aacrjournals.org)
  • As one example, p53 mutations within in situ tumor cells appear to be an independent marker of tumor invasion [3]. (cancernetwork.com)
  • PLoS ONE 2015b, 10(12):e0144170) identified the BRAF variant V595E in approximately 85% of canine TCC cases by DNA sequencing of TCC tumor cells as well as in prostate carcinoma. (laboklin.co.uk)
  • A and B, results of TUNEL assay (Chemicon) used to detect apoptotic tumor cells. (aacrjournals.org)
  • Micrograph of urethral urothelial cell carcinoma. (wikipedia.org)
  • The urethra was sacrificed only if the distal prostatic urethral margin was positive for transitional cell carcinoma. (duke.edu)
  • CONCLUSIONS: The guidelines for urethral resection can be relaxed, increasing the opportunities for orthotopic reconstruction, without placing the patients at increased risk for death of transitional cell carcinoma. (duke.edu)
  • Transitional refers to the histological subtype of the cancerous cells as seen under a microscope. (wikipedia.org)
  • Transitional cell carcinoma is the most common primary neoplasm of the urinary bladder and the entire urinary system. (radiopaedia.org)
  • We report our single institutional experience with retroperitoneal laparoscopic radical nephroureterectomy in patients with upper tract transitional cell carcinoma and compare results to those achieved by the open technique. (nih.gov)
  • A total of 77 patients underwent radical nephroureterectomy for pathologically confirmed upper tract transitional cell carcinoma. (nih.gov)
  • In patients with upper tract transitional cell carcinoma who are candidates for radical nephroureterectomy the retroperitoneal laparoscopic approach satisfactorily duplicates established technical principles of traditional open oncological surgery, while significantly decreasing morbidity from this major procedure. (nih.gov)
  • Endoscopy: Safe option in select upper tract transitional cell carcinomas? (urologytimes.com)
  • Cancun, Mexico -The gold-standard treatment for upper tract transitional cell carcinoma is, without question, nephroureterectomy. (urologytimes.com)
  • Objectives: Nephroureterectomy with removal of the bladder cuff is the standard of care for patients with upper tract transitional cell carcinoma. (eurekamag.com)
  • Methods: Between August 1993 and May 2001, 39 patients underwent laparoscopic RNU for upper tract transitional cell carcinoma (TCC) at our institution. (elsevier.com)
  • Transitional cell carcinoma can be distinguished from adenocarcinoma and carcinoma endometriode exclusively for its histological aspect. (nih.gov)
  • There were 4-318 microscopic foci of intramucosal signet ring cell adenocarcinoma in the six macroscopically normal stomachs (foci size 0.1-10 mm in diameter). (bmj.com)
  • Urinary tract with a transitional cell carcinoma growing in the bladder neck and down the urethra. (marvistavet.com)
  • Needle-tract implantation following US-guided fine-needle aspiration biopsy of transitional cell carcinoma of the bladder, urethra, and prostate. (dogcancerblog.com)
  • A physical exam and ultrasound revealed that she has a mass in her vagina and abnormal tissue in her urethra and abnormal cells in her bladder. (dolforums.com.au)
  • Transitional cell carcinoma (TCC) is a cancerous tumor most commonly found in the urinary bladder and the urethra. (bluepearlvet.com)
  • About 10% of transitional cell carcinomas of the ureteral tract arise in the renal pelvis. (oncologynurseadvisor.com)
  • Sarcomatoid transitional cell carcinoma originating from a duplicated renal pelvis. (malacards.org)
  • Sarcomatoid transitional cell carcinoma of the renal pelvis. (malacards.org)
  • Currently, immunotherapy with Bacillus Calmette-Guerin (BCG) is the most effective treatment for superficial bladder carcinoma, but treatment-related toxicity may limit its use in some patients. (chiro.org)
  • Tumor foci derived from TCCSUP cells remained superficial with an average depth of invasion of 14 ± 8 μm (microns). (aacrjournals.org)
  • Bacillus Calmette-Guerin (BCG) is a common intravesical agent utilized for superficial transitional cell carcinoma of the bladder. (canjurol.com)
  • This article concerns itself with transitional cell carcinomas of the ureters specifically. (radiopaedia.org)
  • These cells also line other parts of the urinary tract, so TCC can also occur in the lining of the kidneys and the ureters, too. (medicalnewstoday.com)
  • Association between lymph node yield and survival among patients undergoing radical nephroureterectomy for urothelial carcinoma of the upper tract. (urotoday.com)
  • As shown in intracranial metastasis of other urinary tract carcinoma, this case occurred in the setting of uncontrolled systemic disease and led to dismal prognosis in spite of aggressive interventional modalities. (biomedsearch.com)
  • Localized/early transitional cell carcinomas can also be treated with infusions of Bacille Calmette-Guérin into the bladder. (wikipedia.org)
  • Computed tomography (CT) scanning is becoming increasingly sensitive for the staging of early transitional cell carcinoma (TCC). (medscape.com)
  • If the White Blood Cell Count was not depressed, then I increase the dose to 6mg/M2 and then 6.5 mg/M2 incrementally or until symptoms regress. (caninecancerawareness.org)
  • Chemotherapy is sometimes used in the treatment of urothelial carcinoma. (nyp.org)
  • Investigation of CK subtypes may be more powerful than morphology alone in clinical studies of transitional cell carcinomas as CK expression profiles have been related to treatment response in other tumour types. (bmj.com)
  • Until recently, there was no standard second-line treatment for advanced urothelial carcinoma. (springermedizin.de)
  • The treatment of bladder carcinoma is an area of active research owing to lack of evidence of any treatment modality. (eurekaselect.com)
  • Retroperitoneal lymph node dissection (RPLD) in conjunction with nephroureterectomy in the treatment of infiltrative transitional cell carcinoma (TCC) of the upper urinary tract: impact on survival. (semanticscholar.org)
  • Nephroureterectomy for treating upper urinary tract transitional cell carcinoma: Time to change the treatment paradigm? (semanticscholar.org)